GSK plc 6-K, filed Jul 28, 2021
GSK plc (GSK)
6-K
2021-07-28
For: 2021-07-28
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on July 28, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
|
Issued:
Wednesday, 28 July 2021, London U.K.
|
|
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15%
CER
Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER
+71% CER
|
|
|
|
|
Highlights
|
|
|
|
|
|
Sales growth driven by strong commercial execution and favourable
prior year comparison
|
|
|
●
|
Pharmaceuticals
£4.2 billion +3% AER, +12% CER with growth in New and
Specialty products (+25% CER) including Respiratory +36% CER,
Immuno-Inflammation +46% CER, Oncology +69% CER, total HIV +14%
CER
|
|
●
|
Vaccines
£1.6 billion +39% AER, +49% CER reflecting strong growth in
Meningitis +46% CER, Established Vaccines +28% CER, Shingrix +1% CER with improved
performance notably in the US and £258 million pandemic
adjuvant sales. Continue to expect strong growth from Shingrix in H2
|
|
●
|
Consumer
Healthcare £2.3 billion -4% AER, +3% CER (+7% CER excluding
divestments/brands under review)
|
|
|
|
|
Effective cost control supports delivery of adjusted earnings per
share growth
|
|
|
●
|
Total
Group operating margin 20.7%. Total EPS 27.9p -39% AER, -28%
CER
|
|
●
|
Adjusted
Group operating margin 26.7%. Adjusted EPS 28.1p +46% AER, +71% CER
(H1 -10% AER, +2% CER). This included a contribution to growth from
COVID-19 solutions of approximately +20% AER, +21% CER in Q2 (+7%
AER, +7% CER in H1)
|
|
●
|
Q2 net
cash flow from operations £1.3 billion. Free cash flow
£316 million
|
|
|
|
|
Continued R&D delivery and strengthening of
pipeline
|
|
|
●
|
FDA rolling review of cabotegravir for prevention of HIV (PrEP)
completed
|
|
●
|
Positive
phase III headline results for daprodustat, potential
transformative medicine for anaemia due to chronic kidney
disease
|
|
●
|
3 new
strategic collaborations announced, iTeos, Alector* and Halozyme
strengthen pipeline in next generation immuno-oncology,
immuno-neurology and HIV
|
|
●
|
Emergency
use authorisations for sotrovimab; Phase III started for Sanofi-GSK
adjuvanted COVID-19 vaccine and EMA rolling review
initiated
|
|
|
|
|
Investor Update in June outlined new outlooks for growth and plans
to maximise shareholder value
|
|
|
●
|
GSK
expects to deliver step-change in sales, operating profit growth
and performance from 2022, driven by high quality Vaccines and
Specialty Medicines portfolio and late-stage pipeline
|
|
●
|
Proposed
demerger to create new world-leading Consumer Healthcare company
confirmed for mid-2022
|
|
|
|
|
Confident in delivering 2021 EPS guidance and reconfirm 2022
outlook
|
|
|
●
|
2021
Adjusted EPS to decline by mid-to-high single-digit percentage at
CER
|
|
●
|
2022
meaningful improvements expected in revenues and
margins
|
|
●
|
2021
guidance and 2022 outlook exclude any contribution from COVID-19
solutions
|
|
|
|
|
Dividend of 19p/share declared for Q2 2021. Continue to expect
80p/share for 2021
|
|
|
|
|
|
Emma Walmsley, Chief Executive Officer, GSK said:
“GSK delivered an
excellent performance in Q2. We expect this positive momentum to
continue through the second half of the year driving us towards the
better end of our earnings guidance range for 2021, and meaningful
performance improvement in 2022. We continue to strengthen our
pipeline and are advancing well towards separation. Our clear
priority is to focus on execution, unlocking the value of Consumer
Healthcare and delivering the step-change in growth and performance
we now see for GSK.”
|
|
The Total results are presented in
summary on page 2 and under ‘Financial performance’ on
pages 12 and 27 and Adjusted results reconciliations are presented
on pages 23, 24, 38 and 39. Adjusted results are a non-IFRS measure
that may be considered in addition to, but not as a substitute for,
or superior to, information presented in accordance with IFRS.
Adjusted results are defined on page 10 and £% or AER% growth,
CER% growth, free cash flow and other non-IFRS measures are defined
on page 67, COVID-19 solutions are also defined on page 67. GSK
provides guidance on an Adjusted results basis only, for the
reasons set out on page 11. All expectations, guidance and targets
regarding future performance and dividend payments should be read
together with ‘Outlook, assumptions and cautionary
statements’ on pages 68 and 69. * Subject to HSR
clearance.
|
|
Q2 2021 results
|
|||||||||||
|
|
Q2 2021
|
|
Growth
|
|
H1 2021
|
|
Growth
|
||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,092
|
|
6
|
|
15
|
|
15,510
|
|
(7)
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
1,675
|
|
(41)
|
|
(30)
|
|
3,368
|
|
(31)
|
|
(21)
|
|
Total
earnings per share
|
27.9p
|
|
(39)
|
|
(28)
|
|
49.4p
|
|
(36)
|
|
(27)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,158
|
|
23
|
|
43
|
|
4,039
|
|
(9)
|
|
3
|
|
Adjusted
earnings per share
|
28.1p
|
|
46
|
|
71
|
|
51.0p
|
|
(10)
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
cash from operating activities
|
1,292
|
|
(53)
|
|
|
|
1,623
|
|
(56)
|
|
|
|
Free
cash flow
|
316
|
|
(84)
|
|
|
|
313
|
|
(87)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2021 guidance
|
|
We reconfirm our guidance range for 2021 for a decline of mid to
high-single digit percent Adjusted EPS at CER, excluding any
contribution from COVID-19 solutions.
In
2021, as planned we will continue to increase investment in our
pipeline, build on our top-line momentum for key growth drivers and
largely complete readiness for separation. Assuming healthcare
systems and consumer trends approach normality in the second half
of the year, we continue to expect Pharmaceutical revenue to grow
flat to low-single digits at CER and Consumer Healthcare revenue to
grow low to mid-single digits at CER (excluding brands
divested/under review) with above market growth. For our Vaccines
business, as noted at the time of announcing full-year 2020
results, we anticipated disruption during the first half of the
year, given governments’ prioritisation of COVID-19
vaccination programmes and ongoing measures to contain the
pandemic. This was expected to impact adult and adolescent
immunisations, including Shingrix, notably in the US and this is
reflected in our first-half year 2021 Vaccines performance. We are
encouraged by the rate at which COVID-19 vaccinations are being
deployed in many countries, particularly the US and UK, which
provides support for healthcare systems returning to normal, though
we are seeing global differentiation in the pace of deployment in
other major markets. There remains, however, uncertainty as to the
impact of COVID-19, the speed of deployment of mass immunisation
programmes and easing of pandemic conditions. In the second half of
the year we continue to expect strong recovery and contribution to
growth but, with Shingrix
sales recovering more slowly in ex-US markets, we now expect
Vaccines revenue for 2021 to be broadly flat. We remain confident
in the underlying demand for our Vaccine products.
Our strong Q2 2021 performance gives us confidence that, providing
we continue to see improving demand for adult vaccinations through
the balance of 2021, as well as healthcare systems and consumer
trends approaching normality, we are likely to deliver full-year
Adjusted EPS towards the better end of our guidance range which is
for a decline of mid-to-high single-digit percentage at CER
excluding any contribution from COVID-19 solutions.
2021 COVID-19 solutions expectations
In H1
2021, we had COVID-19 solution sales of £276 million including
£260 million of pandemic vaccines of which £258 million
were pandemic adjuvant sales and £16 million of the treatment
sotrovimab. The contribution to H1 Adjusted EPS was approximately
7%. For the full year, we expect that the COVID-19 solutions will
contribute approximately between 4% to 6% of Adjusted EPS growth.
The outcome within that range is dependent upon the success of
sotrovimab contracting for 2021, and of pandemic adjuvant
contracting for 2022 and the resulting potential charges within
COGS as we continue to manufacture for this potential.
All
expectations, guidance and targets regarding future performance and
dividend payments should be read together with ‘Outlook,
assumptions and cautionary statements’ on pages 68 and 69. If
exchange rates were to hold at the closing rates on 30 June 2021
($1.39/£1, €1.17/£1 and Yen 153/£1) for the
rest of 2021, the estimated negative impact on 2021 Sterling
turnover growth would be 5% and if exchange gains or losses were
recognised at the same level as in 2020, the estimated negative
impact on 2021 Sterling Adjusted EPS growth would be around
10%.
|
|
Results presentation
|
|
|
A
webcast of the quarterly results presentation hosted by Emma
Walmsley, GSK CEO, will be held at 2pm BST on 28 July 2021.
Presentation materials will be published on www.gsk.com prior to
the webcast and a transcript of the webcast will be published
subsequently.
Information
available on GSK’s website does not form part of, and is not
incorporated by reference into, this Results
Announcement.
|
|
|
Operating performance – Q2 2021
|
|
Turnover
|
Q2 2021
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
4,229
|
|
3
|
|
12
|
|
Vaccines
|
1,571
|
|
39
|
|
49
|
|
Consumer
Healthcare
|
2,292
|
|
(4)
|
|
3
|
|
|
|
|
|
|
|
|
Group
turnover
|
8,092
|
|
6
|
|
15
|
|
|
|
|
|
|
|
|
Operating performance – H1 2021
|
|
Turnover
|
H1 2021
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
8,111
|
|
(5)
|
|
2
|
|
Vaccines
|
2,795
|
|
(5)
|
|
-
|
|
Consumer
Healthcare
|
4,604
|
|
(12)
|
|
(7)
|
|
|
|
|
|
|
|
|
Group
turnover
|
15,510
|
|
(7)
|
|
(1)
|
|
|
|
|
|
|
|
|
Group turnover was £15,510 million in the six months, down 7%
AER, 1% CER.
Pharmaceuticals turnover in the six months was £8,111 million,
down 5% AER but up 2% CER, with growth from Respiratory and HIV
partly offset by declines in Established Pharmaceuticals. In the
first half of last year, the additional COVID-19 related demand
experienced towards the end of the first quarter was broadly
reversed in the second quarter. In the current year, the market
environment continues to be impacted by COVID-19, impacting our
Established Pharmaceuticals products in International and Europe
regions.
Vaccines turnover declined 5% AER, but was flat at CER to
£2,795 million, primarily driven by pandemic adjuvant sales,
offset by the adverse impact of the COVID-19 pandemic on
Shingrix. Vaccines turnover excluding pandemic vaccines
declined 14% AER, 9% CER.
Consumer Healthcare turnover for the six months declined 12% AER,
7% CER to £4,604 million largely driven by the divestment
programme which completed in Q1 2021 as well as the H1 2020
comparative including a particularly strong first quarter given
accelerated purchasing due to the COVID-19 pandemic.
Operating profit
Total operating profit was £3,368 million in H1 2021 compared
with £4,864 million in H1 2020. The total operating margin was
21.7%. The decrease in total operating profit primarily reflected
an unfavourable comparison to the net profit on disposal in Q2 2020
of the Horlicks and other Consumer brands and resultant sale of
shares in Hindustan Unilever.
Adjusted operating profit was £4,039 million, 9% lower than H1
2020 at AER, but 3% higher at CER on a turnover decline of 1% CER.
The Adjusted operating margin of 26.0% was 0.4 percentage points
lower at AER, but 1.1 percentage points higher on a CER basis than
in H1 2020. The
increase in Adjusted operating profit primarily reflected a benefit
from incremental pandemic adjuvant sales, sales growth in
Pharmaceuticals and tight control of ongoing costs including
reduced promotional and variable spending across all three
businesses as a result of the COVID-19 lockdowns, favourable legal
settlements compared to increased legal costs in 2020 and benefits
from continued restructuring across the Group. This was partly
offset by an adverse mix in Vaccines as well as higher supply chain
costs and under-recoveries, divestments in Consumer Healthcare and
increased investment in R&D across Vaccines and
Pharmaceuticals.
Earnings per share
Total
EPS was 49.4p, compared with 77.0p in H1 2020. This primarily
reflected an unfavourable comparison to the net profit on disposal
in Q2 2020 of the Horlicks
and other Consumer brands partly offset by the related loss on sale
of the shares in Hindustan Unilever. These factors were partly
offset by lower major restructuring costs and lower re-measurement
charges on the contingent consideration liabilities. In Q2 2021 a
credit of £325 million to Taxation was recorded resulting from
the revaluation of deferred tax assets following enactment of the
proposed change of the UK corporation tax rate from 19% to 25%
(effective 2023).
Adjusted
EPS was 51.0p compared with 56.9p in H1 2020, down 10% AER but up
2% CER, on a 3% CER increase in Adjusted operating profit
reflecting incremental pandemic adjuvant sales, sales increases in
Pharmaceuticals, tight cost control and favourable legal
settlements, lower interest costs, a lower non-controlling interest
allocation of Consumer Healthcare and ViiV profits, partly offset
by lower non-pandemic sales in Vaccines, primarily Shingrix and a higher effective tax
rate. The contribution to growth from COVID-19 solutions was
approximately 7% AER, 7% CER.
Cash flow
The net cash inflow from operating activities for the six months
was £1,623 million (H1 2020: £3,725 million). Free cash
inflow was £313 million for the six months (H1 2020:
£2,480 million inflow). The decrease primarily reflected
adverse exchange impacts, reduction in trade receivables in H1 2020
as a result of collections following strong sales in Q1 2020,
adverse timing of returns and rebates and taxes compared to Q2 2020
and increased inventory, increased purchases of intangible assets
and reduced proceeds from disposal of intangible assets as the
Consumer Brands Disposal programme is now complete. This was partly
offset by increased operating profit and lower dividends to
non-controlling interests.
|
|
R&D pipeline
|
|
We focus on the science of the immune system, human genetics and
advanced technologies to develop Vaccines and Specialty Medicines
in four core therapeutic areas - Infectious Diseases, HIV, Oncology
and Immunology/Respiratory. We also remain open to opportunities
outside these core therapy areas where there are scale
opportunities consistent with the science of the immune system and
human genetic validation.
As disclosed at the Investor Update on 23 June 2021, the company
has a robust late-stage R&D pipeline with many assets having
the potential to be first-in-class or best-in-class, as well as
offering significant strategic lifecycle opportunities. The
late-stage pipeline is expected to help deliver the sales ambition
set by the company for 2021-2026 and beyond.
Our R&D pipeline currently comprises 63 Vaccines and Specialty
Medicines.
Pipeline news flow highlights since Q1 2021 Results are listed
below in chronological order.
|
|
Infectious diseases
|
|
Shingrix
|
|
|
●
|
Received
FDA approval for the prevention of HZ (herpes zoster) in adults who
are immunodeficient or immunosuppressed due to disease or
therapy.
|
|
Klebsiella
candidate vaccine
|
|
|
●
|
Started
a Phase I study of the tetravalent bioconjugate candidate vaccine
Kleb4V that includes O-antigen combined with our proprietary
adjuvant system.
|
|
MenABCWY
candidate vaccine
|
|
|
●
|
Started
a Phase I study of the Meningococcal ABCWY 2nd generation
candidate vaccine to assess immunogenicity and safety in healthy
adolescents and adults aged 15 to 25 years who had previously been
vaccinated with the MenACWY vaccine.
|
|
Priorix
|
|
|
●
|
Delivered
a regulatory submission to the FDA for immunisation against
measles, mumps and rubella.
|
|
Respiratory
Syncytial Virus (RSV) candidate vaccines
|
|
|
●
|
Positive
phase I/II data for RSV maternal candidate vaccine (recombinant
PreF protein) presented at the European Society for Paediatric
Infectious Diseases annual meeting.
|
|
●
|
Development
of phase II RSV paediatric candidate vaccine (viral vector)
discontinued following assessment that target efficacy profile was
unlikely to be met.
|
|
HIV
|
|
Cabenuva
(cabotegravir/rilpivirine)
|
|
|
●
|
Presented
data from the CUSTOMIZE study showing new long-acting HIV regimen
Cabenuva can be
successfully implemented in a broad range of US healthcare
practices, even during COVID-19.
|
|
Dovato (dolutegravir/lamivudine)
|
|
|
●
|
Presented
data from SALSA the second Dovato switch study confirming
non-inferior efficacy and no virologic failure versus a broad range
of regimens of at least 3 drugs.
|
|
GSK3810109
(VRC-N6LS; broadly neutralising antibody)
|
|
|
●
|
Started
a Phase II study with a broadly neutralising antibody for the
treatment of HIV.
|
|
Cabotegravir
(long-acting integrase inhibitor)
|
|
|
●
|
Completed
a rolling submission of a new drug application with the FDA for
long-acting cabotegravir for the prevention of HIV.
|
|
ENHANZE®
drug delivery
technology
|
|
|
●
|
ViiV
Healthcare and Halozyme entered a global collaboration and license
agreement to enable the development of
“ultra-long-acting” medicines for HIV.
|
|
Oncology
|
|
GSK4428859
(EOS-448; TIGIT antagonist)
|
|
|
●
|
Announced
a co-development and co-commercialisation collaboration with iTeos
Therapeutics for EOS-448, an anti-TIGIT monoclonal
antibody.
|
|
Zejula (niraparib; PARP
inhibitor)
|
|
|
●
|
The
MOONSTONE study evaluating the efficacy and safety of niraparib
plus dostarlimab in the treatment of platinum resistant ovarian
cancer without a known BRCAm has been stopped as a pre-planned
analysis suggested the data would not meet the high bar set for
this single arm ORR study.
|
|
feladilimab
(GSK3359609; ICOS agonist)
|
|
|
●
|
The
ENTRÉE-Lung sub study 1 investigating feladilimab plus
docetaxel versus docetaxel alone did not meet its primary endpoint
at the interim analysis.
|
|
Immunology/Respiratory
|
|
AL001
and AL101 (progranulin-elevating monoclonal
antibodies)
|
|
|
●
|
Announced
a global collaboration in immuno-neurology with Alector* for two
clinical stage first-in-class monoclonal antibodies for
neurodegenerative diseases.
|
|
*
|
Subject to HSR
clearance
|
|
Benlysta (belimumab)
|
|
|
●
|
Announced
European Commission approval of Benlysta in combination with background
immunosuppressive therapies for the treatment of adult patients
with active lupus nephritis in Europe.
|
|
Nucala (mepolizumab)
|
|
|
●
|
EMA
accepted a filing submission for the 40mg pre-filled syringe to
provide an appropriate paediatric presentation for at home
administration.
|
|
Opportunity driven
|
|
daprodustat
(oral hypoxia-inducible factor prolyl hydroxylase
inhibitor)
|
|
|
●
|
Announced
positive headline results from five Phase III studies of
daprodustat for patients with anaemia due to chronic kidney
disease.
|
|
COVID-19
|
|
Vaccines
collaborations
|
|
|
●
|
EMA initiated a rolling review of Sanofi and GSK’s COVID-19
adjuvanted protein recombinant vaccine candidate,
Vidprevtyn.
|
|
●
|
Sanofi
and GSK started a global Phase III clinical efficacy study of their
vaccine candidate. Pending positive Phase III outcomes and
regulatory reviews, the vaccine could be approved in Q4
2021.
|
|
●
|
Medicago
and GSK announced positive interim Phase II results for their
adjuvanted COVID-19 vaccine candidate, demonstrating that
neutralising antibody responses were ten-times higher than in
people recovering from COVID-19.
|
|
●
|
Sanofi
and GSK announced Phase II results for their vaccine candidate,
achieving strong rates of neutralising antibody responses, in line
with those measured in people who have recovered from COVID-19
across all adult age groups.
|
|
Sotrovimab
(GSK4182136; dual-action SARS-CoV-2 monoclonal
antibody)
|
|
|
●
|
Vir and
GSK announced the first patient was dosed in the Phase III
COMET-TAIL study investigating intramuscular sotrovimab for
patients with mild/moderate COVID-19.
|
|
●
|
Vir and
GSK announced full results from the Phase III COMET-ICE trial
demonstrating a 79% reduction in hospitalisation for more than 24
hours or death due to any cause with early treatment with
sotrovimab in adult patients with mild-to-moderate COVID-19 who are
at high risk of progression to severe disease.
|
|
●
|
Received
Emergency Use Authorisation from the FDA for the treatment of
mild-to-moderate COVID-19 in high-risk adults and paediatric
patients.
|
|
●
|
Received
a positive scientific opinion from the EMA’s Committee for
Human Medicinal Products (CHMP) for the early treatment of
COVID-19. The CHMP opinion under Article 5(3) can now be considered
by the national authorities in EU member states when taking
evidence-based decisions on the early use of the medicine prior to
marketing authorisation.
|
|
Contents
|
Page
|
|
|
|
|
Total
and Adjusted results
|
10
|
|
Financial
performance – Q2 2021
|
12
|
|
Financial
performance – H1 2021
|
27
|
|
Cash
generation
|
43
|
|
Returns
to shareholders
|
44
|
|
|
|
|
Income
statements
|
46
|
|
Statement
of comprehensive income – three months ended 30 June
2021
|
47
|
|
Statement
of comprehensive income – six months ended 30 June
2021
|
48
|
|
Pharmaceuticals
turnover – three months ended 30 June 2021
|
49
|
|
Pharmaceuticals
turnover – six months ended 30 June 2021
|
50
|
|
Vaccines
turnover – three months ended 30 June 2021
|
51
|
|
Vaccines
turnover – six months ended 30 June 2021
|
52
|
|
Balance
sheet
|
53
|
|
Statement
of changes in equity
|
54
|
|
Cash
flow statement – six months ended 30 June 2021
|
55
|
|
Segment
information
|
56
|
|
Legal
matters
|
58
|
|
Additional
information
|
59
|
|
Reconciliation
of cash flow to movements in net debt
|
65
|
|
Net
debt analysis
|
65
|
|
Free
cash flow reconciliation
|
65
|
|
Principal
risks and uncertainties
|
66
|
|
Reporting
definitions
|
67
|
|
Outlook,
assumptions and cautionary statements
|
68
|
|
Directors’
responsibility statement
|
70
|
|
Independent
review report
|
71
|
|
Contacts
|
|
GSK –
one of the world’s leading research-based pharmaceutical and
healthcare companies – is committed to improving the quality
of human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
|
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madeleine
Breckon
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kristen
Neese
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
|
Registered
in England & Wales:
No. 3888792
|
|
|
|
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8 9GS
|
|
Total and Adjusted results
|
|
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined below and other non-IFRS measures are
defined on page 67.
GSK
believes that Adjusted results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Adjusted
results exclude the following items from Total results, together
with the tax effects of all of these items:
|
|
●
|
amortisation
of intangible assets (excluding computer software)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
Major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant legal charges (net of insurance recoveries) and
expenses on the settlement of litigation and government
investigations; other operating income other than royalty income,
and other items including the one-off impact of the revaluation of
deferred tax assets and liabilities following enactment of the
increase in the headline rate of UK corporation tax from 19% to 25%
(effective 2023)
|
|
●
|
separation
costs
|
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses are retained within both Total and Adjusted
results.
As
Adjusted results include the benefits of Major restructuring
programmes but exclude significant costs (such as significant
legal, major restructuring and transaction items) they should not
be regarded as a complete picture of the Group’s financial
performance, which is presented in Total results. The exclusion of
other Adjusting items may result in Adjusted earnings being
materially higher or lower than Total earnings. In particular, when
significant impairments, restructuring charges and legal costs are
excluded, Adjusted earnings will be higher than Total
earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy, or following material acquisitions. Costs, both
cash and non-cash, of these programmes are provided for as
individual elements are approved and meet the accounting
recognition criteria. As a result, charges may be incurred over a
number of years following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
The
enactment of the increase in the headline rate of UK Corporation
tax from 19% to 25% (effective 2023) resulted in a credit of
£325 million in Q2 2021. Due to the magnitude, GSK has
reported this credit as an Adjusting item in Q2 2021 and H1 2021 so
that it does not obscure the key trends in the Group’s
performance for the period.
Reconciliations
between Total and Adjusted results, providing further information
on the key Adjusting items, are set out on pages 23, 24, 38 and
39.
GSK
provides earnings guidance to the investor community on the basis
of Adjusted results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
|
|
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of
dolutegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 86% of the Total
earnings and 83% of the Adjusted earnings of ViiV Healthcare for
2020.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, principally
dolutegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent re-measurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each period. At 30 June
2021, the liability, which is discounted at 8.0%, stood at
£5,199 million, on a post-tax basis.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance of the relevant products in the previous quarter. These
payments reduce the balance sheet liability and hence are not
recorded in the income statement. The cash payments made to
Shionogi by ViiV Healthcare in H1 2021 were £419
million.
Because
the liability is required to be recorded at the fair value of
estimated future payments, there is a significant timing difference
between the charges that are recorded in the Total income statement
to reflect movements in the fair value of the liability and the
actual cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 52 and 53 of the Annual Report
2020.
|
|
Financial performance – Q2 2021
|
|
Total results
|
|
The
Total results for the Group are set out below.
|
|
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,092
|
|
7,624
|
|
6
|
|
15
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(2,554)
|
|
(2,449)
|
|
4
|
|
9
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,538
|
|
5,175
|
|
7
|
|
18
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,642)
|
|
(2,709)
|
|
(2)
|
|
3
|
|
Research
and development
|
(1,222)
|
|
(1,301)
|
|
(6)
|
|
-
|
|
Royalty income
|
77
|
|
75
|
|
3
|
|
-
|
|
Other
operating income/(expense)
|
(76)
|
|
1,610
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
1,675
|
|
2,850
|
|
(41)
|
|
(30)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
7
|
|
1
|
|
|
|
|
|
Finance
expense
|
(192)
|
|
(229)
|
|
|
|
|
|
Loss on
disposal of interest in associates
|
(36)
|
|
-
|
|
|
|
|
|
Share
of after tax profits of
associates
and joint ventures
|
16
|
|
19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,470
|
|
2,641
|
|
(44)
|
|
(32)
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
68
|
|
(201)
|
|
|
|
|
|
Tax rate %
|
(4.6)%
|
|
7.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,538
|
|
2,440
|
|
(37)
|
|
(26)
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
143
|
|
177
|
|
|
|
|
|
Profit
attributable to shareholders
|
1,395
|
|
2,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,538
|
|
2,440
|
|
(37)
|
|
(26)
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
27.9p
|
|
45.5p
|
|
(39)
|
|
(28)
|
|
|
|
|
|
|
|
|
|
|
Adjusted results
The
Adjusted results for the Group are set out below. Reconciliations
between Total results and Adjusted results for Q2 2021 and Q2 2020
are set out on pages 23 and 24.
|
|
|
Q2 2021
|
||||||
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,092
|
|
100
|
|
6
|
|
15
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(2,348)
|
|
(29.0)
|
|
4
|
|
9
|
|
Selling,
general and administration
|
(2,498)
|
|
(30.9)
|
|
(1)
|
|
5
|
|
Research
and development
|
(1,165)
|
|
(14.4)
|
|
(1)
|
|
6
|
|
Royalty
income
|
77
|
|
1.0
|
|
3
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,158
|
|
26.7
|
|
23
|
|
43
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before tax
|
1,989
|
|
|
|
29
|
|
50
|
|
Adjusted
profit after tax
|
1,623
|
|
|
|
32
|
|
54
|
|
Adjusted
profit attributable to shareholders
|
1,407
|
|
|
|
47
|
|
72
|
|
|
|
|
|
|
|
|
|
|
Adjusted
earnings per share
|
28.1p
|
|
|
|
46
|
|
71
|
|
|
|
|
|
|
|
|
|
|
Operating profit by business
|
Q2 2021
|
||||||
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
2,094
|
|
49.5
|
|
11
|
|
25
|
|
Pharmaceuticals
R&D*
|
(853)
|
|
|
|
(6)
|
|
1
|
|
|
|
|
|
|
|
|
|
|
Total
Pharmaceuticals
|
1,241
|
|
29.3
|
|
27
|
|
46
|
|
Vaccines
|
514
|
|
32.7
|
|
94
|
|
>100
|
|
Consumer
Healthcare
|
498
|
|
21.7
|
|
(4)
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
2,253
|
|
27.8
|
|
28
|
|
46
|
|
Corporate
& other unallocated costs
|
(95)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,158
|
|
26.7
|
|
23
|
|
43
|
|
|
|
|
|
|
|
|
|
|
*
|
Operating
profit of Pharmaceuticals R&D segment, which is the
responsibility of the Chief Scientific Officer and President,
R&D. It excludes ViiV Healthcare R&D expenditure, which is
reported within the Pharmaceuticals segment.
|
|
Turnover
|
|
Pharmaceuticals turnover
|
|
|
Q2 2021
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Respiratory
|
717
|
|
25
|
|
36
|
|
HIV
|
1,235
|
|
4
|
|
14
|
|
Immuno-inflammation
|
233
|
|
32
|
|
46
|
|
Oncology
|
119
|
|
55
|
|
69
|
|
|
|
|
|
|
|
|
New and
Specialty
|
2,304
|
|
14
|
|
25
|
|
Established
Pharmaceuticals
|
1,925
|
|
(8)
|
|
-
|
|
|
|
|
|
|
|
|
|
4,229
|
|
3
|
|
12
|
|
|
|
|
|
|
|
|
US
|
1,986
|
|
10
|
|
23
|
|
Europe
|
963
|
|
3
|
|
6
|
|
International
|
1,280
|
|
(7)
|
|
3
|
|
|
|
|
|
|
|
|
|
4,229
|
|
3
|
|
12
|
|
|
|
|
|
|
|
|
Pharmaceuticals
turnover in the quarter was £4,229 million, up 3% AER, 12%
CER.
In the
quarter results show significant growth over the same quarter last
year, driven by strong growth in New and Specialty products,
favourable US RAR adjustments and a prior year comparator that was
impacted by destocking in the quarter.
Q2 2020
was weakened as it was the first full quarter of COVID-19 pandemic
impact and included some destocking of COVID-19 related additional
demand in the first quarter. The impact of this prior year
destocking accounted for approximately 3 percentage points of
growth at CER in the current quarter. The prior period RAR
adjustment, including the impact of lower than expected Medicaid
usage on a number of products, also accounted for approximately 4
percentage points of growth at CER in the quarter.
New and
Specialty sales of £2,304 million grew 14% AER, 25% CER, with
ongoing growth from Respiratory, Oncology, Immuno-Inflammation and
HIV.
Respiratory
sales were up 25% AER, 36% CER, to £717 million, on growth of
Trelegy and Nucala, and our Immuno-Inflammation and
Oncology portfolios continue to show double digit growth. HIV sales
grew 4% AER, 14% CER, to £1,235 million, including the
favourable impact on growth of prior year destocking, with growth
of Dovato exceeding the
decline in Triumeq. Sales
of Established Pharmaceuticals declined 8% AER but were flat at
CER, to £1,925 million.
In the
US, sales grew 10% AER, 23% CER. Continued growth of Nucala, Trelegy, Benlysta and Dovato was supplemented by growth in
Established Products. This reflected strong demand for Established
Respiratory products in the COVID-19 environment and certain supply
challenges faced by generic competitor products, plus the benefit
of a favourable prior period RAR adjustment in the
quarter.
In
Europe, sales grew 3% AER, 6% CER, including the favourable impact
on growth of prior year destocking, with double digit growth of
Trelegy, Nucala, Anoro,
Benlysta and Zejula.
HIV two-drug regimens growth exceeded the declines in Tivicay and Triumeq. The Established
Pharmaceuticals portfolio declined 8% AER, 6% CER, impacted by
generic competition including Seretide, Duodart and
Volibris.
International
declined 7% AER but grew 3% CER. Growth from the Respiratory
portfolio and HIV including the impact of tender phasing was offset
by declines in Established Pharmaceuticals which continue to be
impacted by COVID-19 suppressed antibiotics markets and increased
generic competition in Japan on Xyzal and Avolve.
Respiratory
Total
Respiratory sales were up 25% AER, 36% CER, with growth from
Trelegy, Nucala and Anoro. International
Respiratory sales grew 41% AER, 51% CER including Nucala, up 22% AER, 35% CER and
Trelegy up more than 100%
AER and CER including the impact of Trelegy Asthma launched in Japan in Q4
2020. In Europe, Respiratory grew 23% AER, 25% CER with double
digit growth of Anoro,
Trelegy and Nucala.
In the US, Respiratory grew 22% AER, 37% CER, driven by
Trelegy and Nucala and the impact of a prior period
RAR adjustment.
Sales
of Nucala were £292
million in the quarter and grew 21% AER, 32% CER, with consistent,
strong growth across all three regions. US sales were up 21% AER,
35% CER to £182 million and International sales of £45
million grew 22% AER, 35% CER. Europe sales of £65 million
grew 20% AER, 22% CER.
Trelegy sales were up 50% AER, 64% CER to £291 million
driven by growth in all regions. In the US, sales benefited from
the new asthma indication approved and launched in Q3 2020, with
sales up 46% AER, 64% CER. In Europe, sales grew 36% AER, 36% CER
and in International, where Trelegy asthma was approved in Japan in
Q4 2020, sales grew more than 100% AER and CER to £38
million.
HIV
HIV
sales were £1,235 million with growth of 4% AER, 14% CER in
the quarter. Q2 2021 growth benefited from customer destocking in
the Q2 2020 comparator, following customer stock building in Q1
2020 due to COVID-19 mainly in the US and Europe. Together with the
timing of Tivicay tenders
in International, these two factors accounted for 5 and 6
percentage points of CER growth respectively. The mature portfolio
drove 1 percentage point of CER decline. Triumeq sales were £466 million,
down 20% AER, 13% CER and Tivicay sales were £407 million,
up 9% AER, 21% CER.
New HIV
products Juluca, Dovato,
Rukobia and Cabenuva
delivered sales of £330 million representing 27% of the total
HIV portfolio. Sales of the two drug regimens Juluca and Dovato were £132 million and
£184 million respectively with combined growth of 75% AER, 90%
CER. Rukobia sales were
£10 million. Cabenuva,
the first long acting injectable, recorded quarterly sales of
£4 million.
In the
US, total sales were £716 million with decline of 3% AER, but
growth of 8% CER. New HIV products delivered sales of £216
million, including: Dovato
£102 million growth of more than 100% AER and more than 100%
CER, Juluca £101
million growth of 12% AER, 24% CER, Rukobia £10 million and
Cabenuva £3 million.
Combined Tivicay and
Triumeq sales were
£488 million declining 17% AER, 7% CER. In Europe, total sales
were £292 million with growth of 8% AER, 11% CER. New HIV
products delivered sales of £97 million, including:
Dovato £69 million
growth of more than 100% AER and more than 100% CER and
Juluca £27 million
growth of 29% AER, 38% CER. Combined Tivicay and Triumeq sales were £184 million
declining 17% AER, 14% CER.
Oncology
Sales
of Zejula, the PARP
inhibitor treatment for ovarian cancer were £98 million in the
quarter, up 27% AER, 38% CER. Sales included £54 million in
the US and £41 million in Europe.
Blenrep for the treatment of patients with relapsed or
refractory multiple myeloma was approved and launched in the US and
Europe in Q3 2020 and reported sales of £21 million in the
quarter.
Immuno-inflammation
Sales
of Benlysta in the quarter
were up 21% AER, 34% CER to £214 million, including the impact
of lupus nephritis launches in US and Japan in H2 2020. In the
quarter, the first sales of sotrovimab, the monoclonal antibody
treatment for COVID-19 patients at risk of hospitalisation totalled
£16 million.
Established Pharmaceuticals
Sales
of Established Pharmaceuticals in the quarter were £1,925
million, down 8% AER, but flat at CER.
Established
Respiratory products declined 2% AER but grew 6% CER to £1,089
million. The ongoing impact of generic competition to Xyzal in Japan, and to Advair/Seretide in all regions was more
than offset by the favourable impact on growth from destocking last
year and the benefit of a prior period RAR adjustment in the
quarter.
The
remainder of the Established Pharmaceuticals portfolio declined by
14% AER, 7% CER to £836 million driven by generic impacts
including Volibris in
Europe and Avolve/Avodart
in Japan.
|
|
Vaccines turnover
|
|
|
Q2 2021
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Meningitis
|
225
|
|
35
|
|
46
|
|
Influenza
|
33
|
|
>100
|
|
>100
|
|
Shingles
|
295
|
|
(9)
|
|
1
|
|
Established
Vaccines
|
758
|
|
21
|
|
28
|
|
|
|
|
|
|
|
|
|
1,311
|
|
16
|
|
24
|
|
Pandemic
Vaccines
|
260
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
Total
Vaccines
|
1,571
|
|
39
|
|
49
|
|
|
|
|
|
|
|
|
US
|
796
|
|
78
|
|
97
|
|
Europe
|
297
|
|
3
|
|
6
|
|
International
|
478
|
|
20
|
|
26
|
|
|
|
|
|
|
|
|
|
1,571
|
|
39
|
|
49
|
|
|
|
|
|
|
|
|
Vaccines turnover grew 39% AER, 49% CER to £1,571 million,
primarily driven by pandemic adjuvant sales, higher demand for
DTPa-containing vaccines in the US and higher demand for
Bexsero
in the US and in
Europe.
Vaccines turnover excluding pandemic vaccines grew 16% AER, 24% CER
to £1,311 million.
Vaccines performance in Q2 2021 continued to be affected by lower
demand for routine adult vaccination due to COVID-19 vaccination
programme deployment mainly in the US and Europe. Demand for
paediatric and adolescent vaccination improved as lifting of
stay-at-home directives resulted in increased visits to healthcare
practitioners and points of vaccination.
Higher demand in the US for paediatric and adolescent vaccination
represented a recovery trend including partial catch up of
prior period missed vaccinations and
CDC purchasing patterns.
In Q2 2020, sales declined 29% CER due to the significant impact of
the COVID-19 pandemic across all regions.
Meningitis
Meningitis sales grew 35% AER, 46% CER to £225 million.
Bexsero
sales grew 53% AER, 63% CER to
£165 million reflecting higher demand and increased
market share in the US, together with strong performance in Europe
and International.
Menveo sales were up 55% AER, 71% CER to £59
million, primarily driven by higher demand in the US, partly offset
by unfavorable phasing and lower demand in
International.
Influenza
Fluarix/FluLaval sales grew by
more than 100% AER and CER, to £33 million driven by strong
southern hemisphere demand in International.
Shingles
Shingrix declined by 9% AER but grew 1% CER to £295
million. Growth from launches in the UK and in China was mostly
offset by a decline in Germany where COVID-19 related restrictions
and prioritisation of COVID-19 mass vaccination limited
Shingrix uptake. In the US,
increased market demand in the current quarter was offset by
favourable prior period returns and rebates movements and channel
stocking in the comparator quarter.
Established Vaccines
Hepatitis vaccines sales were up 28% AER, 38% CER to £110
million, largely driven by favourable US wholesaler purchasing
patterns and higher demand in paediatric vaccines, partly offset by
higher competitive pressure in the US.
Sales of DTPa-containing vaccines (Infanrix, Pediarix and Boostrix) grew by 45% AER, 55% CER. Infanrix/Pediarix
sales rose 14% AER, 24% CER to
£136 million, reflecting increased channel stock replenishment
on wholesaler purchasing patterns and demand in the US,
partly offset by a change in
recommendation for the dosing schedule in Germany and supply
constraints in Europe. Boostrix sales grew 92% AER and more than 100% CER to
£146 million largely driven by higher demand in the US
and in International.
Rotarix sales were up 3%
AER, 9% CER to £132 million,
reflecting increased channel stocking on wholesaler purchasing
patterns in the US.
Synflorix sales declined by 6%
AER, 2% CER to £97 million, primarily due to lower tender
demand in Emerging Markets and Europe.
MMRV vaccines sales were flat at AER, but grew 6% CER to £54
million, largely driven by favourable phasing in
International.
Pandemic Vaccines
Pandemic vaccines sales of £260 million included £258
million of pandemic adjuvant sales, which represented delivery of
around two-thirds of the contracted volumes with the US and
Canadian governments.
|
|
Consumer Healthcare turnover
|
|
|
|
|
Q2 2021
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Oral
health
|
|
|
663
|
|
4
|
|
12
|
|
Pain
relief
|
|
|
563
|
|
6
|
|
13
|
|
Vitamins,
minerals and supplements
|
|
|
359
|
|
(11)
|
|
(6)
|
|
Respiratory
health
|
|
|
210
|
|
(2)
|
|
6
|
|
Digestive
health and other
|
|
|
464
|
|
(5)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,259
|
|
(1)
|
|
7
|
|
Brands
divested/under review
|
|
|
33
|
|
(72)
|
|
(70)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,292
|
|
(4)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
US
|
|
|
734
|
|
(11)
|
|
(1)
|
|
Europe
|
|
|
608
|
|
1
|
|
3
|
|
International
|
|
|
950
|
|
(1)
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,292
|
|
(4)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare sales declined 4% AER, but increased 3% CER to
£2,292 million in the second quarter with growth in the
quarter more than offsetting dilution from the divestment programme
which completed at the end of Q1 2021.
Sales excluding brands divested/under review declined 1% AER but
increased 7% CER supported by a favourable comparative in Q2 2020
as a result of destocking. In the second quarter last year, sales
at CER excluding brands divested/under review were flat at
pro-forma and included the reversal of the benefit of the
accelerated purchases in the first quarter in 2020 across all
categories as a result of the COVID-19 pandemic. Additionally, Q2
2020 benefited by approximately 2 percentage points from increased
retailer stocking ahead of a systems cutover in North America which
reversed in Q3 2020.
On a 2 year CAGR sales excluding brands divested/under review
increased 3%. Consistent with disclosure in the Q1 2021 press
release given the significant volatility with the Q1 2020 and Q2
2020 comparatives as a result of the COVID-19 pandemic the 2 year
category CAGRs are shared below. These are shared for the first
half of this year only, as this is more indicative of underlying
trends than looking at the quarters in isolation.
International sales excluding brands divested/under review grew
high single digit CER with strong performance in the emerging
markets such as China, Latin America, and India.
Oral health
Oral health sales increased 4% AER, 12% CER to £663 million.
In Q2 2020 Oral health sales declined low single digit.
Sensodyne
delivered growth in the mid-teens
compared with low single digit growth in Q2 2020, reflecting
underlying brand strength and continued innovation particularly in
the US, Middle East and Africa and India. Gum health and Denture care reported mid-teens
growth and high single digit growth respectively in the second
quarter. Denture care sales, whilst up in the quarter helped by a
favourable comparative to Q2 2020, continued to be negatively
impacted by social distancing due to the pandemic. On a 2 year CAGR
growth was 5%, consistent with the 2 year CAGR for the first
quarter and similar to trends in the second half of
2020.
Pain relief
Pain relief sales increased 6% AER, 13% CER to £563 million.
In Q2 2020 Pain relief sales declined low single digit on a
pro-forma basis. Advil and Panadol increased double digit helped by favourable comparatives due to
destocking in Q2 2020. Voltaren increased low double digit helped by the
successful Rx to OTC switch in May last year. The 2 year CAGR for
the category grew 5% similar to the 2 year CAGR in the prior
quarter.
Vitamins, minerals and supplements
Vitamins,
minerals and supplements sales declined 11% AER, 6% CER to
£359 million. In Q2 2020 Vitamins, minerals and supplements
sales increased high-teens per cent on a pro-forma basis.
Centrum grew low single
digit although this was more than offset by a double digit decline
in Emergen-C which faced
particularly challenging comparatives (sales almost doubled in Q2
2020) and a mid-single digit decline in Caltrate. On a 2 year CAGR the category
grew 6%.
Respiratory health
Respiratory health sales declined 2% AER but increased 6% CER to
£210 million. In Q2 2020 Respiratory health sales declined low
double digit on a pro-forma basis. Theraflu and Robitussin declined significantly. Otrivin and Flonase were up double digit although helped by easier
comparatives in Q2 2020 when sales declined in the high teens. The
category 2 year CAGR declined 3%. Seasonal cold, flu and nasal
brands continued to be adversely impacted by the weaker cold and
flu season as a result of the pandemic and social distancing, and
its 2 year CAGR declined high single digit. In contrast the allergy
2 year CAGR was up high single digit.
Digestive health and other
Digestive
health and other brands sales declined 5% AER but increased 3% CER
at £464 million. In Q2 2020 Digestive health and other brands
had decreased low-single digits on a pro-forma basis. Digestive
health products saw double digit growth, with Smokers health
products up mid single digit and Skin health products up high teens
although brands such as Chapstick remained muted given reduced
impulse purchase. The 2 year category CAGR was flat.
|
|
Operating performance
|
|
Cost of sales
Total
cost of sales as a percentage of turnover was 31.6%, 0.6 percentage
points lower at AER and 1.8 percentage points lower in CER terms
compared with Q2 2020. This included a similar level of write downs
in manufacturing sites as in Q2 2020.
Excluding
these and other Adjusting items, Adjusted cost of sales as a
percentage of turnover was 29.0%, 0.5 percentage points lower at
AER and 1.6 percentage points lower at CER compared with Q2 2020.
This reflected price benefits in Pharmaceuticals, including the
benefit from a prior period RAR adjustment, reduced supply chain
costs and a favourable mix in Vaccines, including pandemic
adjuvants.
Selling, general and administration
Total
SG&A costs as a percentage of turnover were 32.6%, 2.9
percentage points lower at AER and 3.6 percentage points lower at
CER compared with Q2 2020.
Excluding
Adjusting items, Adjusted SG&A costs as a percentage of
turnover were 30.9%, 2.3 percentage points lower at AER than in Q2
2020 and 3.0 percentage points lower on a CER basis. Adjusted
SG&A costs declined 1% AER but increased 5% CER which reflected
increased investment for launches in Pharmaceuticals and Vaccines
compared to reduced spend in Q2 2020 as a result of the COVID-19
lockdowns partly offset by continued tight control of ongoing costs
and the continuing benefit of restructuring in Pharmaceuticals,
Consumer Healthcare and support functions.
Research and development
Total
R&D expenditure was £1,222 million (15.1% of turnover),
down 6% AER, but flat at CER, including a decrease in impairments.
Adjusted R&D expenditure was £1,165 million (14.4% of
turnover), 1% lower at AER, 6% higher at CER than in Q2
2020.
Pharmaceuticals
R&D expenditure was £883 million, down 4% AER, up 3% CER,
primarily driven by increases in the Specialty portfolio excluding
Oncology, offset by a net reduction compared to Q2 2020 in
Oncology. Efficiency savings continue from the implementation of
the One Development programme for Pharmaceuticals and Vaccines as
part of the Separation preparation restructuring programme and
variable spending as a result of COVID-19 lockdowns.
In the
Specialty portfolio excluding Oncology there has been an increase
in investment, specifically related to our two key COVID-19
treatment programmes (sotrovimab and otilimab) and also in
bepirovirsen, the HBV antisense oligonucleotide programme,
depemokimab, the anti-IL5 for asthma and otilimab for rheumatoid
arthritis. There has also been an increase in spend for the early
stage non-Oncology research portfolio. In Oncology there is
increased investment from the progression of Zejula, Jemperli and NY-ESO, offset by a
reduction in spend on Blenrep following successful approval
in Q3 2020 and feladilimab following the decision to terminate two
studies in April.
R&D
expenditure in Vaccines was £224 million, up 28% AER, 34% CER,
reflecting increased investment in meningitis and RSV, partly
offset by efficiency savings from the implementation of the One
Development programme. R&D expenditure in Consumer Healthcare
was £58 million.
Royalty income
Royalty
income was £77 million (Q2 2020: £75 million), up 3% AER,
but flat at CER.
|
|
Other operating income/(expense)
Net
other operating expense of £76 million (Q2 2020: £1,610
million income) primarily reflected accounting charges of £101
million (Q2 2020: £368 million) arising from the
re-measurement of the contingent consideration liabilities related
to the acquisitions of the former Shionogi-ViiV Healthcare joint
venture and the former Novartis Vaccines business and the
liabilities for the Pfizer put option and Pfizer and Shionogi
preferential dividends in ViiV Healthcare. This included a
re-measurement charge of £125 million (Q2 2020: £343
million) for the contingent consideration liability due to
Shionogi, primarily as a result of the unwinding of the discount
for £92 million and a charge for £33 million from
adjustments to sales forecasts partly offset by updated exchange
rate assumptions. This was partly offset by fair value gains on
investments and a number of asset disposals. Q2 2020 included the
net profit on disposal of the Horlicks and other Consumer brands of
£2,304 million partly offset by the loss on sale of the shares
in Hindustan Unilever of £476 million.
|
|
Operating profit
Total
operating profit was £1,675 million in Q2 2021 compared with
£2,850 million in Q2 2020. This primarily reflected an
unfavourable comparison to the net profit on disposal of the
Horlicks and other Consumer
brands of £2,304 million partly offset by the related loss on
sale of the shares in Hindustan Unilever of £476
million.
Excluding
these and other Adjusting items, Adjusted operating profit was
£2,158 million, 23% higher than Q2 2020 at AER, 43% higher at
CER on a turnover increase of 15% CER. The Adjusted operating
margin of 26.7% was 3.7 percentage points higher at AER, and 5.6
percentage points higher on a CER basis than in Q2
2020.
The increase in Adjusted operating profit primarily reflected
leverage from a favourable comparison to destocking in Q2 2020 in
Pharmaceuticals and Consumer Healthcare, £258 million of
pandemic adjuvant sales, increased demand for Meningitis and
DTPa-containing Vaccines and a favourable prior period RAR
adjustment in Pharmaceuticals, continued tight control of ongoing
costs and benefits from continued restructuring across the
business. This was partly offset by increased investment behind
launches and increased investment in R&D.
Contingent
consideration cash payments which are made to Shionogi and other
companies reduce the balance sheet liability and hence are not
recorded in the income statement. Total contingent consideration
cash payments in Q2 2021 amounted to £205 million (Q2 2020:
£240 million). This included cash payments made to Shionogi of
£203 million (Q2 2020: £232 million).
Adjusted operating profit by business
Pharmaceuticals
operating profit was £1,241 million, up 27% AER, and 46% CER
on a turnover increase of 12% CER. The operating margin of 29.3%
was 5.6 percentage points higher at AER than in Q2 2020 and 7.2
percentage points higher on a CER basis. This primarily reflected
positive leverage from a favourable comparison to destocking in Q2
2020 and a favourable prior period RAR adjustment, as well as
continued tight control of ongoing costs and benefits from
continued restructuring. This was partly offset by increased
investment in R&D.
Vaccines
operating profit was £514 million, up 94% AER, >100% CER on
a turnover increase of 49% CER. The operating margin of 32.7% was
9.3 percentage points higher at AER than in Q2 2020 and 11.4
percentage points higher on a CER basis. This was primarily driven
by positive operating leverage from sales growth including pandemic
adjuvant sales mix. This was partly offset by higher R&D spend
to support key strategic priorities along with increased SG&A
investment to support business growth.
Consumer
Healthcare operating profit was £498 million, down 4% AER but
up 5% CER on a turnover increase of 3% CER. The operating margin of
21.7% was 0.1 percentage point lower at AER but 0.5 percentage
points higher on a CER basis than in Q2 2020. The margin increase
at CER reflected incremental synergy benefits from the Pfizer Joint
Venture integration, price increases and leverage from volume
growth partially offset by the impact of divestments (1.1
percentage points), increased advertising and promotion investment
to resume to pre-COVID-19 levels, increased commodity costs and
investment into manufacturing sites.
Net finance costs
Total
net finance costs were £185 million compared with £228
million in Q2 2020. Adjusted net finance costs were £185
million compared with £227 million in Q2 2020. The decrease
primarily reflects reduced interest expense from lower debt levels,
favourable movements in foreign exchange rates and reduced swap
interest expense on foreign currency hedges.
Share of after tax profits of associates and joint
ventures
The
share of after tax profits of associates and joint ventures was
£16 million (Q2 2020: £19 million).
Loss on disposal of interest in associates
In the
quarter the net loss on disposal of interest in associates was
£36 million, primarily driven by a loss on disposal of the
interest in Innoviva Inc.
Taxation
The
credit of £68 million represented an effective tax rate on
Total results of (4.6)% (Q2 2020: 7.6%) and reflected the different
tax effects of the various Adjusting items including a credit of
£325 million in Q2 2021 resulting from the revaluation of
deferred tax assets following enactment of the proposed change of
UK corporation tax rate from 19% to 25% (effective 1 April 2023).
Q2 2020 reflected the disposal of the Horlicks and other Consumer brands and
the subsequent disposal of shares received in Hindustan Unilever.
Tax on Adjusted profit amounted to £366 million and
represented an effective Adjusted tax rate of 18.4% (Q2 2020:
20.5%).
Issues
related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2020. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods which are open and not yet
agreed by tax authorities. The ultimate liability for such matters
may vary from the amounts provided and is dependent upon the
outcome of agreements with relevant tax authorities.
Non-controlling interests
The
allocation of Total earnings to non-controlling interests amounted
to £143 million (Q2 2020: £177 million). The reduction
was primarily due to a reduced allocation of Consumer Healthcare
Joint Venture profits of £76 million (Q2 2020: £137
million), partly offset by an increased allocation of ViiV
Healthcare profits of £60 million (Q2 2020: £24 million),
including reduced credits for re-measurement of contingent
consideration liabilities.
The
allocation of Adjusted earnings to non-controlling interests
amounted to £216 million (Q2 2020: £267 million). The
reduction in allocation primarily reflected a reduced allocation of
Consumer Healthcare Joint Venture profits of £108 million (Q2
2020: £138 million) and a reduced allocation of ViiV
Healthcare profits of £101 million (Q2 2020: £113
million), as well as lower net profits in some of the Group’s
other entities with non-controlling interests.
Earnings per share
Total
EPS was 27.9p, compared with 45.5p in Q2 2020. This primarily
reflected an unfavourable comparison to the net profit on disposal
in Q2 2020 of the Horlicks
and other Consumer brands partly offset by the related loss on sale
of the shares in Hindustan Unilever, as well as by a credit of
£325 million to Taxation in Q2 2021 resulting from the
revaluation of deferred tax assets following enactment of the
proposed change of UK corporation tax rate from 19% to 25%
(effective 1 April 2023).
Adjusted
EPS was 28.1p compared with 19.2p in Q2 2020, up 46% AER and 71%
CER, on a 43% CER increase in Adjusted operating profit reflecting
sales increases in Pharmaceuticals and Consumer Healthcare
including a benefit from destocking in Q2 2020 and increased
Vaccines sales including pandemic adjuvant sales, lower interest
costs, a lower effective tax rate and a lower non-controlling
interest allocation of Consumer Healthcare and ViiV profits. The
contribution to growth from COVID-19 solutions was approximately
20% AER, 21% CER.
Currency impact on Q2 2021 results
The
results for Q2 2021 are based on average exchange rates,
principally £1/$1.40, £1/€1.16 and £1/Yen 152.
Comparative exchange rates are given on page 59. The period-end
exchange rates were £1/$1.39, £1/€1.17 and
£1/Yen 153.
In the
quarter, turnover increased 6% AER, 15% CER. Total EPS was 27.9p
compared with 45.5p in Q2 2020. Adjusted EPS was 28.1p compared
with 19.2p in Q2 2020, up 46% AER and 71% CER. The adverse currency
impact primarily reflected the strengthening in Sterling,
particularly against the US as well as Yen. Exchange gains or
losses on the settlement of intercompany transactions had a 1%
impact on the negative currency impact of 25 percentage points on
Adjusted EPS.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for Q2
2021 and Q2 2020 are set out below.
|
|
Three months ended 30 June 2021
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Separation
costs
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
8,092
|
|
|
|
|
|
|
8,092
|
|
Cost of sales
|
(2,554)
|
171
|
|
28
|
7
|
|
|
(2,348)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
5,538
|
171
|
|
28
|
7
|
|
|
5,744
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and
administration
|
(2,642)
|
|
|
83
|
|
(13)
|
74
|
(2,498)
|
|
Research and
development
|
(1,222)
|
25
|
6
|
26
|
|
|
|
(1,165)
|
|
Royalty income
|
77
|
|
|
|
|
|
|
77
|
|
Other operating
income/(expense)
|
(76)
|
|
|
1
|
123
|
(48)
|
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
1,675
|
196
|
6
|
138
|
130
|
(61)
|
74
|
2,158
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance costs
|
(185)
|
|
|
|
|
|
|
(185)
|
|
Loss on
disposal of interest in associates
|
(36)
|
|
|
|
|
36
|
|
-
|
|
Share
of after tax profits
of
associates and joint
ventures
|
16
|
|
|
|
|
|
|
16
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
1,470
|
196
|
6
|
138
|
130
|
(25)
|
74
|
1,989
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
68
|
(38)
|
(1)
|
(29)
|
(33)
|
(319)
|
(14)
|
(366)
|
|
Tax rate %
|
(4.6)%
|
|
|
|
|
|
|
18.4%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
1,538
|
158
|
5
|
109
|
97
|
(344)
|
60
|
1,623
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
143
|
|
|
|
73
|
|
|
216
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
1,395
|
158
|
5
|
109
|
24
|
(344)
|
60
|
1,407
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
27.9p
|
3.2p
|
0.1p
|
2.1p
|
0.5p
|
(6.9)p
|
1.2p
|
28.1p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average
number
of shares
(millions)
|
5,004
|
|
|
|
|
|
|
5,004
|
|
|
––––––––––––
|
|
|
|
|
|
|
––––––––––––
|
|
Three months ended 30 June 2020
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Separation
costs
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
7,624
|
|
|
|
|
|
|
7,624
|
|
Cost of sales
|
(2,449)
|
180
|
(2)
|
12
|
10
|
|
|
(2,249)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
5,175
|
180
|
(2)
|
12
|
10
|
|
|
5,375
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and
administration
|
(2,709)
|
|
3
|
182
|
(20)
|
(4)
|
18
|
(2,530)
|
|
Research and
development
|
(1,301)
|
17
|
116
|
(2)
|
|
(1)
|
|
(1,171)
|
|
Royalty income
|
75
|
|
|
|
|
|
|
75
|
|
Other operating
income/(expense)
|
1,610
|
|
|
1
|
359
|
(1,970)
|
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
2,850
|
197
|
117
|
193
|
349
|
(1,975)
|
18
|
1,749
|
|
|
|
|
|
|
|
|
|
|
|
Net finance costs
|
(228)
|
|
|
|
|
1
|
|
(227)
|
|
Share of after tax profits
of associates and joint
ventures
|
19
|
|
|
|
|
|
|
19
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
2,641
|
197
|
117
|
193
|
349
|
(1,974)
|
18
|
1,541
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(201)
|
(34)
|
(22)
|
(47)
|
(56)
|
47
|
(3)
|
(316)
|
|
Tax rate %
|
7.6%
|
|
|
|
|
|
|
20.5%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
2,440
|
163
|
95
|
146
|
293
|
(1,927)
|
15
|
1,225
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
177
|
|
|
|
90
|
|
|
267
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
2,263
|
163
|
95
|
146
|
203
|
(1,927)
|
15
|
958
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
45.5p
|
3.2p
|
1.9p
|
2.9p
|
4.1p
|
(38.7)p
|
0.3p
|
19.2p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of shares
(millions)
|
4,977
|
|
|
|
|
|
|
4,977
|
|
|
––––––––––––
|
|
|
|
|
|
|
––––––––––––
|
|
Major restructuring and integration
Within
the Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete.
|
|
Total
Major restructuring charges incurred in Q2 2021 were £138
million (Q2 2020: £193 million), analysed as
follows:
|
|
|
Q2 2021
|
|
Q2
2020
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018
major restructuring
programme
(incl. Tesaro)
|
3
|
|
-
|
|
3
|
|
30
|
|
15
|
|
45
|
|
Consumer
Healthcare Joint
Venture
integration
programme
|
35
|
|
(2)
|
|
33
|
|
82
|
|
15
|
|
97
|
|
Separation
Preparation
restructuring
programme
|
104
|
|
(10)
|
|
94
|
|
42
|
|
3
|
|
45
|
|
Combined
restructuring and
integration
programme
|
4
|
|
4
|
|
8
|
|
(3)
|
|
9
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
146
|
|
(8)
|
|
138
|
|
151
|
|
42
|
|
193
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
charges of £104 million under the Separation Preparation
programme primarily arose from restructuring of some administrative
functions as well as commercial pharmaceuticals and R&D
functions. Non-cash credits of £10 million primarily reflected
a write back on disposal of a site.
Cash
charges of £35 million on the Consumer Healthcare Joint
Venture programme primarily related to severance and integration
costs.
Total
cash payments made in Q2 2021 were £197 million (Q2 2020:
£163 million), £114 million (Q2 2020: £20 million)
relating to the Separation Preparation restructuring programme, a
further £48 million (Q2 2020: £65 million) relating to
the Consumer Healthcare Joint Venture integration programme,
£21 million (Q2 2020: £47 million) under the 2018 major
restructuring programme including the settlement of certain charges
accrued in previous quarters and £14 million (Q2 2020:
£31 million) for the existing Combined restructuring and
integration programme.
The
analysis of Major restructuring charges by business was as
follows:
|
|
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
|
|
|
|
|
Pharmaceuticals
|
54
|
|
44
|
|
Vaccines
|
4
|
|
(14)
|
|
Consumer
Healthcare
|
36
|
|
105
|
|
|
94
|
|
135
|
|
Corporate
& central functions
|
44
|
|
58
|
|
|
|
|
|
|
Total
Major restructuring costs
|
138
|
|
193
|
|
|
|
|
|
|
The
analysis of Major restructuring charges by Income statement line
was as follows:
|
|
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
|
|
|
|
|
Cost of
sales
|
28
|
|
12
|
|
Selling,
general and administration
|
83
|
|
182
|
|
Research
and development
|
26
|
|
(2)
|
|
Other
operating income
|
1
|
|
1
|
|
|
|
|
|
|
Total
Major restructuring costs
|
138
|
|
193
|
|
|
|
|
|
|
The
benefit in the quarter from restructuring programmes was £0.1
billion, with contributions from the Consumer Healthcare Joint
Venture integration and the Separation Preparation restructuring
programme.
|
|
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £130 million (Q2 2020:
£349 million). This included a net £101 million
accounting charge for the re-measurement of the contingent
consideration liabilities related to the acquisitions of the former
Shionogi-ViiV Healthcare joint venture and the former Novartis
Vaccines business and the liabilities for the Pfizer put option and
Pfizer and Shionogi preferential dividends in ViiV
Healthcare.
|
|
Charge/(credit)
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
venture
(including
Shionogi preferential dividends)
|
125
|
|
343
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(37)
|
|
10
|
|
Contingent
consideration on former Novartis Vaccines business
|
13
|
|
15
|
|
Other
adjustments
|
29
|
|
(19)
|
|
|
|
|
|
|
Total
transaction-related charges
|
130
|
|
349
|
|
|
|
|
|
|
The £125 million charge relating to the contingent
consideration for the former Shionogi-ViiV Healthcare joint venture
represented an increase in the valuation of the contingent
consideration due to Shionogi, primarily as a result of the unwind
of the discount for £92 million and a charge of £33
million primarily from adjustments to sales forecasts partly offset
by updated exchange rate assumptions. The £37 million credit
relating to the ViiV Healthcare put option and Pfizer preferential
dividends represented a reduction in the valuation of the put
option primarily as a result of lower cash following preference
dividend payments.
The
ViiV Healthcare contingent consideration liability is fair valued
under IFRS. The potential impact of the COVID-19 pandemic remains
uncertain and at 30 June 2021, it has been assumed that there will
be no significant impact on the long-term value of the liability.
This position remains under review and the amount of the liability
will be updated in future quarters as further information on the
impact of the pandemic becomes available. An explanation of the
accounting for the non-controlling interests in ViiV Healthcare is
set out on page 11.
Divestments, significant legal charges and other items
Divestments
and other items also included fair value gains on investments and a
number of asset disposals and certain other Adjusting items,
including the impact of the proposed change of UK Corporation tax
rate as discussed on page 11. In the quarter, the net loss on
disposal of interests in associates was £36 million, primarily
driven by a loss on disposal of the interest in Innoviva Inc. There
was a credit of £11 million (Q2 2020: £1 million charge)
for significant legal matters arising in the quarter. Significant
legal cash payments were £1 million (Q2 2020: £1
million).
Separation costs
From Q2
2020, the Group started to report additional costs to prepare for
Consumer Healthcare separation. Separation costs incurred in the
quarter were £74 million (Q2 2020: £18
million).
|
|
Financial performance – H1 2021
|
|
Total results
|
|
The
Total results for the Group are set out below.
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
15,510
|
|
16,714
|
|
(7)
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(5,034)
|
|
(5,648)
|
|
(11)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
10,476
|
|
11,066
|
|
(5)
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(5,069)
|
|
(5,625)
|
|
(10)
|
|
(6)
|
|
Research
and development
|
(2,340)
|
|
(2,488)
|
|
(6)
|
|
(1)
|
|
Royalty income
|
168
|
|
142
|
|
18
|
|
18
|
|
Other
operating income/(expense)
|
133
|
|
1,769
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
3,368
|
|
4,864
|
|
(31)
|
|
(21)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
17
|
|
42
|
|
|
|
|
|
Finance
expense
|
(393)
|
|
(458)
|
|
|
|
|
|
Loss on
disposal of interest in associates
|
(36)
|
|
-
|
|
|
|
|
|
Share
of after tax profits of
associates
and joint ventures
|
32
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,988
|
|
4,476
|
|
(33)
|
|
(23)
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(190)
|
|
(357)
|
|
|
|
|
|
Tax rate %
|
6.4%
|
|
8.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
2,798
|
|
4,119
|
|
(32)
|
|
(23)
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
330
|
|
291
|
|
|
|
|
|
Profit
attributable to shareholders
|
2,468
|
|
3,828
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,798
|
|
4,119
|
|
(32)
|
|
(23)
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
49.4p
|
|
77.0p
|
|
(36)
|
|
(27)
|
|
|
|
|
|
|
|
|
|
|
Adjusted results
The
Adjusted results for the Group are set out below. Reconciliations
between Total results and Adjusted results for H1 2021 and H1 2020
are set out on pages 38 and 39.
|
|
|
H1 2021
|
||||||
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
15,510
|
|
100
|
|
(7)
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(4,584)
|
|
(29.6)
|
|
(6)
|
|
(3)
|
|
Selling,
general and administration
|
(4,813)
|
|
(31.0)
|
|
(9)
|
|
(6)
|
|
Research
and development
|
(2,242)
|
|
(14.5)
|
|
(1)
|
|
5
|
|
Royalty
income
|
168
|
|
1.1
|
|
18
|
|
18
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
4,039
|
|
26.0
|
|
(9)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before tax
|
3,696
|
|
|
|
(8)
|
|
4
|
|
Adjusted
profit after tax
|
3,012
|
|
|
|
(11)
|
|
1
|
|
Adjusted
profit attributable to shareholders
|
2,550
|
|
|
|
(10)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
Adjusted
earnings per share
|
51.0p
|
|
|
|
(10)
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Operating profit by business
|
H1 2021
|
||||||
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
4,004
|
|
49.4
|
|
3
|
|
12
|
|
Pharmaceuticals
R&D*
|
(1,644)
|
|
|
|
(6)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Total
Pharmaceuticals
|
2,360
|
|
29.1
|
|
9
|
|
22
|
|
Vaccines
|
820
|
|
29.3
|
|
(27)
|
|
(17)
|
|
Consumer
Healthcare
|
1,033
|
|
22.4
|
|
(20)
|
|
(13)
|
|
|
|
|
|
|
|
|
|
|
|
4,213
|
|
27.2
|
|
(8)
|
|
3
|
|
Corporate
& other unallocated costs
|
(174)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
4,039
|
|
26.0
|
|
(9)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
*
|
Operating profit of Pharmaceuticals
R&D segment, which is the responsibility of the Chief
Scientific Officer and President, R&D. It excludes ViiV
Healthcare R&D expenditure, which is reported within the
Pharmaceuticals segment.
|
|
Turnover
|
|
Pharmaceuticals turnover
|
|
|
H1 2021
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Respiratory
|
1,336
|
|
22
|
|
31
|
|
HIV
|
2,266
|
|
(5)
|
|
1
|
|
Immuno-inflammation
|
413
|
|
26
|
|
37
|
|
Oncology
|
229
|
|
45
|
|
53
|
|
|
|
|
|
|
|
|
New and
Specialty
|
4,244
|
|
7
|
|
14
|
|
Established
Pharmaceuticals
|
3,867
|
|
(15)
|
|
(9)
|
|
|
|
|
|
|
|
|
|
8,111
|
|
(5)
|
|
2
|
|
|
|
|
|
|
|
|
US
|
3,699
|
|
4
|
|
14
|
|
Europe
|
1,913
|
|
(8)
|
|
(7)
|
|
International
|
2,499
|
|
(13)
|
|
(6)
|
|
|
|
|
|
|
|
|
|
8,111
|
|
(5)
|
|
2
|
|
|
|
|
|
|
|
|
Pharmaceuticals
turnover in the six months was £8,111 million, down 5% AER but
up 2% CER with Sterling strengthening over the period. HIV sales
were down 5% AER but up 1% CER, to £2,266 million, with growth
in Juluca and Dovato partly offset by Tivicay and Triumeq. Respiratory sales were up 22%
AER, 31% CER, to £1,336 million, on growth of Trelegy and Nucala. Sales of Established
Pharmaceuticals declined 15% AER, 9% CER to £3,867
million.
In the
first half of last year, the additional COVID-19 related demand
experienced towards the end of the first quarter was broadly
reversed in the second quarter. In the current year, the market
environment continues to be impacted by COVID-19, impacting our
Established Pharmaceuticals products in International and Europe
regions.
In the
US, sales grew 4% AER, 14% CER with continued growth of New and
Specialty products supplemented by growth in Established Products.
This reflected strong demand for Established Respiratory products
in the COVID-19 environment and certain supply challenges faced by
generic competitor products, plus the benefit of a favourable prior
period RAR adjustment.
In
Europe, sales declined 8% AER and 7% CER, with growth of
Trelegy, Nucala, Benlysta
and Oncology products offset by declines in the Established
Pharmaceuticals portfolio. This portfolio was impacted by generic
competition including Seretide,
Duodart and Volibris, lower antibiotic demand, and a one-off
UK Relenza contract last
year. Growth in HIV two-drug regimens was offset by declines in
Tivicay and Triumeq.
International
declined 13% AER, 6% CER. Growth from the Respiratory and HIV
portfolios was offset by declines in Established Pharmaceuticals
which continued to be impacted by COVID-19 suppressed antibiotics
markets and increased generic competition in Japan on Xyzal and Avolve.
Respiratory
Total
Respiratory sales were up 22% AER, 31% CER, with strong growth from
all Regions. International Respiratory sales grew 37% AER, 45% CER
including Nucala up 24%
AER, 34% CER, and Trelegy
up 94% AER and more than 100% CER including the impact of
Trelegy Asthma launched in
Japan in Q4 2020. In Europe, Respiratory grew 12% AER, 12% CER with
double digit growth of Trelegy and high single digit growth of
Nucala. In the US,
Respiratory grew 23% AER, 35% CER, driven by Trelegy and Nucala and the impact of a prior period
RAR adjustment.
Sales
of Nucala were £546
million in the six months and grew 21% AER, 29% CER, with
consistent, strong growth across all three regions. US sales were
up 25% AER, 37% CER to £332 million and International sales of
£87 million grew 24% AER, 34% CER. Europe sales of £127
million grew 9% AER, 9% CER.
Trelegy sales were up 39% AER, 49% CER to £539 million
driven by growth in all regions. In the US, sales benefited from
the new asthma indication approved and launched in Q3 2020, with
sales up 38% AER, 51% CER. In Europe, sales grew 21% AER, 21% CER
and in International, where Trelegy asthma was approved in Japan in
Q4 2020, sales grew 94% AER and more than 100% CER to £68
million.
HIV
HIV
sales were £2,266 million with decline of 5% AER but growth of
1% CER in the six months. Triumeq sales were £902 million,
down 21% AER, 16% CER and Tivicay sales were £708 million,
down 10% AER, 3% CER. In the first six months, growth was reduced
by customer stock building due to COVID-19 in 2020, mainly in the
US and Europe, accounting for 1 percentage point of CER growth. The
mature portfolio drove 1 percentage point of CER
decline.
New HIV
products Juluca, Dovato,
Rukobia and Cabenuva
delivered sales of £592 million representing 26% of the total
HIV portfolio. Sales of the two drug regimens Juluca and Dovato were £244 million and
£325 million, respectively, with combined growth of 55% AER,
65% CER. Rukobia sales were
£17 million. Cabenuva,
the first long acting injectable, recorded half year sales of
£6 million.
In the
US, total sales were £1,313 million with decline of 9% AER and
1% CER. New HIV products delivered sales of £382 million,
including: Dovato £176
million growth of 87% AER and more than 100% CER, Juluca £184 million flat at AER,
but growth of 9% CER, Rukobia £17 million and
Cabenuva £5 million.
Combined Tivicay and
Triumeq sales were
£907 million declining 20% AER, 13% CER. In Europe, total
sales were £579 million with decline of 2% AER, 2% CER. New
HIV products delivered sales of £181 million, including:
Dovato £127 million
growth of more than 100% AER and more than 100% CER and
Juluca £53 million
growth of 18% AER, 20% CER. Combined Tivicay and Triumeq sales were £380 million
declining 21% AER, 21% CER.
Oncology
Sales
of Zejula, the PARP
inhibitor treatment for ovarian cancer were £186 million, up
18% AER, 24% CER. Sales included £105 million in the US and
£77 million in Europe.
Blenrep for the treatment of patients with relapsed or
refractory multiple myeloma was approved and launched in the US and
Europe in Q3 2020. Launches in Europe included four markets in the
first half of the year, and sales globally totalled £42
million.
Immuno-inflammation
Sales
of Benlysta were up 20%
AER, 30% CER to £392 million, including the impact of lupus
nephritis launches in US and Japan in H2 2020.
The
first sales of sotrovimab, the monoclonal antibody treatment for
COVID-19 patients at risk of hospitalisation, totalled £16
million.
Established Pharmaceuticals
Sales
of Established Pharmaceuticals in the six months were £3,867
million, down 15% AER, 9% CER.
Established
Respiratory products declined 9% AER 3% CER to £2,216 million.
This reflects the ongoing impact of generic competition to
Xyzal in Japan, and to
Advair/Seretide globally.
The decline was partially offset by the favourable impact on growth
of favourable prior period RAR adjustments.
The
remainder of the Established Pharmaceuticals portfolio declined by
21% AER, 16% CER to £1,651 million on lower demand for
antibiotics during the COVID-19 pandemic period, the impact of
government mandated changes increasing use of generics in markets
including France, Japan and China and a strong comparator,
including the European Relenza contract.
|
|
Vaccines turnover
|
|
|
H1 2021
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Meningitis
|
415
|
|
6
|
|
12
|
|
Influenza
|
51
|
|
42
|
|
53
|
|
Shingles
|
622
|
|
(36)
|
|
(31)
|
|
Established
Vaccines
|
1,447
|
|
(6)
|
|
(2)
|
|
|
|
|
|
|
|
|
|
2,535
|
|
(14)
|
|
(9)
|
|
Pandemic
Vaccines
|
260
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
2,795
|
|
(5)
|
|
-
|
|
|
|
|
|
|
|
|
US
|
1,301
|
|
(11)
|
|
(3)
|
|
Europe
|
604
|
|
(5)
|
|
(5)
|
|
International
|
890
|
|
6
|
|
10
|
|
|
|
|
|
|
|
|
|
2,795
|
|
(5)
|
|
-
|
|
|
|
|
|
|
|
|
Vaccines turnover declined 5% AER, but was flat at CER to
£2,795 million, primarily driven by pandemic adjuvant sales,
offset by the adverse impact of the COVID-19 pandemic on
Shingrix.
Vaccines turnover excluding pandemic vaccines declined 14% AER, 9%
CER to £2,535 million.
Vaccines performance in the first half of 2021 was affected by
lower demand for routine adult vaccination due to COVID-19
vaccination programme deployment mainly in the US and Europe,
resulting in lower Shingrix sales. Demand for paediatric and adolescent
vaccination improved, particularly in the second quarter, as
lifting of stay-at-home directives resulted in increased visits to
healthcare practitioners and points of
vaccination.
Higher demand in the US for paediatric and adolescent vaccination
represents a recovery trend related to improved COVID-19 pandemic
conditions.
In the comparator period, vaccines sales declined by 6% CER
primarily driven by the adverse impact of the COVID-19 pandemic in
the second quarter.
Meningitis
Meningitis sales grew 6% AER, 12% CER to £415 million.
Bexsero
sales grew 10% AER, 15% CER to
£299 million, reflecting higher demand together with increased
market share in the US and strong performance in
Europe.
Menveo sales were up 26% AER,
36% CER to £98 million, primarily driven by higher demand and
increased market share in the US.
Influenza
Fluarix/FluLaval sales grew 42%
AER, 53% CER, to £51 million driven by higher southern
hemisphere demand in International.
Shingles
Shingrix declined by 36% AER,
31% CER to £622 million, primarily driven by lower demand in
the US due to prioritised focus on COVID-19 mass vaccination of
older adults together with US channel stocking and
favourable prior period returns and rebates movements in the
comparator period. Growth
from launches in the UK and in China was mostly offset by a decline
in Germany and in Canada where COVID-19 related restrictions and
prioritisation of COVID-19 mass vaccination limited Shingrix uptake.
Established Vaccines
Hepatitis vaccines were down 31% AER, 27% CER to £205 million,
adversely impacted in the US and Europe by lower demand due to
COVID-19 pandemic conditions, travel restrictions in Europe and
competitive pressure in the US market.
Sales of DTPa-containing vaccines (Infanrix, Pediarix and
Boostrix) grew by 5% AER, 11%
CER. Infanrix/Pediarix
sales declined 9% AER, 3% CER to
£272 million, reflecting supply constraints and lower tender
demand in Europe together with the change in recommendation for the
dosing schedule in Germany, partly offset by increased channel
stock replenishment on wholesaler purchasing patterns and demand in
the US. Boostrix sales grew 28% AER, 34% CER to £240 million,
largely driven by higher demand in International together with
favourable US wholesaler purchasing patterns and higher
demand.
Rotarix sales were down 12%
AER, 8% CER to £246 million, reflecting unfavourable phasing
in Emerging Markets.
Synflorix sales declined by 12%
AER, 10% CER to £199 million, primarily due to lower tender
demand in Emerging Markets and Europe.
MMRV vaccines sales grew 5% AER, 9% CER to £117 million,
largely driven by improved supply in International.
Pandemic
Vaccines
Pandemic vaccines sales of £260 million included £258
million of pandemic adjuvant sales, which represented delivery of
around two-thirds of the contracted volumes with the US and
Canadian governments.
|
|
Consumer Healthcare turnover
|
|
|
|
|
H1 2021
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Oral
health
|
|
|
1,358
|
|
(1)
|
|
5
|
|
Pain
relief
|
|
|
1,109
|
|
(3)
|
|
2
|
|
Vitamins,
minerals and supplements
|
|
|
708
|
|
(8)
|
|
(4)
|
|
Respiratory
health
|
|
|
453
|
|
(31)
|
|
(26)
|
|
Digestive
health and other
|
|
|
892
|
|
(5)
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,520
|
|
(7)
|
|
(2)
|
|
Brands
divested/under review
|
|
|
84
|
|
(78)
|
|
(77)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,604
|
|
(12)
|
|
(7)
|
|
|
|
|
|
|
|
|
|
|
US
|
|
|
1,447
|
|
(20)
|
|
(12)
|
|
Europe
|
|
|
1,219
|
|
(10)
|
|
(9)
|
|
International
|
|
|
1,938
|
|
(8)
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,604
|
|
(12)
|
|
(7)
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare sales for the six months sales declined 12%
AER, 7% CER to £4,604 million largely driven by the divestment
programme which completed in Q1 2021 as well as the H1 2020
comparative including a particularly strong first quarter given
accelerated purchasing due to the COVID-19 pandemic.
Sales excluding brands divested/under review declined 2% CER, which
compares to the same six months last year when sales increased 7%
CER excluding brands divested/under review on a pro-forma basis. In
addition to benefitting from the particularly strong first quarter
last year, H1 2020 was helped by 1 percentage point from the
increased retailer stocking ahead of a systems cutover in North
America, which subsequently reversed in the third quarter of 2020.
Consistent with the Q2 2021 results, the first half 2 year CAGRs
are shared below, to give more perspective on underlying
performance trends adjusting for the volatility in the first two
quarters last year as a result of the pandemic. The unprecedented
negative impact of a historically weak seasonal cold flu and nasal
products continued to adversely impact sales growth.
International sales excluding brands divested/under review grew
high single digit CER in emerging markets, with double digit growth
in China, Latin America, India and high single digit growth in
Middle East and Africa.
Oral health
Oral health sales decreased 1% AER and increased 5% CER to
£1,358 million. In H1 2020 Oral health sales increased mid
single digit. Sensodyne delivered high single digit growth reflecting
underlying brand strength, continued innovation and good consumer up take in traditional retail
and ecommerce channels particularly in India and in the
US. Gum health delivered double digit growth, whilst
Denture care was flat. On a 2 year CAGR growth for the category was
up 5%.
Pain relief
Pain relief sales decreased 3% AER and increased 2% CER to
£1,109 million. In H1 2020, Pain relief sales increased mid
single digit on a pro-forma basis. Advil declined in the high teens (compared to double
digit growth in H1 2020) which was more than offset mainly by
growth in the mid-teens for Voltaren and to a lesser extent by Panadol which was up low single digit. Voltaren growth was helped by the successful Rx to OTC
switch in the US last year. On a 2 year CAGR growth for the
category was up 4%.
Vitamins, minerals and supplements
Vitamins,
minerals and supplements sales declined 8% AER, 4% CER to £708
million. In H1 2020 Vitamins, minerals and supplements sales
increased high-teens per cent on a pro-forma basis. Caltrate delivered double digit growth
and Centrum grew low single
digit (compared with growth in the high teens in H1 2020) although
this was more than offset by double digit decline in Emergen-C which faced a particularly
challenging comparator in H1 2020 when volumes almost doubled. On a
2 year CAGR the growth for the category was up 7%.
Respiratory health
Respiratory health sales declined 31% AER, 26% CER to £453
million. In H1 2020, Respiratory health sales increased low double
digit on a pro-forma basis benefiting from accelerated purchasing
in the first quarter particularly on cold and flu products.
Theraflu
and Robitussin declined double digit given the continued impact
of a significantly lower cold and flu season due to the COVID-19
pandemic and social distancing and a strong H1 2020
comparator. Otrivin declined double digit and Flonase was flat. On a 2 year CAGR the category was down
10%, with seasonal cold, flu and nasal down mid-teens and allergy
up low single digit.
Digestive health and other
Digestive
health and other brands sales decreased 5% AER and increased 2% CER
at £892 million. In H1 2020, Digestive health and other brands
declined low-single digits on a pro-forma basis. Growth in
Digestive health products offset a decline Smokers’ health
products, with Skin health products up low single digit. On a 2
year CAGR the growth for the category was flat.
|
|
Operating performance
|
|
Cost of sales
Total
cost of sales as a percentage of turnover was 32.5%, 1.3 percentage
points lower at AER and 2.4 percentage points lower in CER terms
compared with H1 2020. This primarily reflected lower write downs
in a number of manufacturing sites and the unwind in Q1 2020 of the
fair market value uplift on inventory arising on completion of the
Consumer Healthcare Joint Venture with Pfizer.
Excluding
these and other Adjusting items, Adjusted cost of sales as a
percentage of turnover was 29.6%, 0.5 percentage points higher at
AER but 0.4 percentage points lower at CER compared with H1 2020.
This reflected price benefits in Pharmaceuticals, including the
benefit from a prior period RAR adjustment, as well as reduced
supply chain costs partly offset by an adverse mix in Vaccines,
primarily due to the reduction in Shingrix sales in the US partly offset by
beneficial pandemic adjuvant mix, as well as higher supply chain
costs and under-recoveries resulting from lower
demand.
Selling, general and administration
Total
SG&A costs as a percentage of turnover were 32.7%, 1.0
percentage points lower at AER and 1.6 percentage points lower at
CER compared with H1 2020.
Excluding
Adjusting items, Adjusted SG&A costs as a percentage of
turnover were 31.0%, 0.8 percentage points lower at AER than in H1
2020 and 1.3 percentage points lower on a CER basis. Adjusted
SG&A costs declined 9% AER, 6% CER which reflected the tight
control of ongoing costs and reduced variable spending across all
three businesses as a result of the COVID-19 lockdowns, and the
continuing benefit of restructuring in Pharmaceuticals, Consumer
Healthcare and support functions. Over a third of this decline also
reflected a favourable legal settlement in H1 2021 compared to
increased legal costs in 2020.
Research and development
Total
R&D expenditure was £2,340 million (15.1% of turnover),
down 6% AER, 1% CER, including a decrease in major restructuring
charges and impairments. Adjusted R&D expenditure was
£2,242 million (14.5% of turnover), 1% lower at AER, 5% higher
at CER than in H1 2020.
Pharmaceuticals
R&D expenditure was £1,717 million, down 3% AER, up 3%
CER, primarily driven by the increased investment in our Specialty
portfolio offset by a net reduction in Oncology. Efficiency savings
continued from the implementation of the One Development programme
for Pharmaceuticals and Vaccines as part of the Separation
Preparation restructuring programme and variable spending as a
result of COVID-19 lockdowns.
The
growth of the Specialty portfolio excluding Oncology investment was
driven primarily by our two COVID-19 treatment programmes
(sotrovimab and otilimab) as well as the progression of a number of
other key programmes, including bepirovirsen, the HBV antisense
oligonucleotide programme, depemokimab, the anti-IL5 for asthma and
otilimab for rheumatoid arthritis. In Oncology there has been
increased investment in Zejula and Jemperli, offset by a reduction in
spend on Blenrep following
successful approval in Q3 2020 and feladilimab following the
decision to terminate two studies in April.
R&D
expenditure in Vaccines was £412 million, up 24% AER, 26% CER,
reflecting increased investment in clinical programmes for
meningitis ABCWY and RSV, partly offset by efficiency savings from
the implementation of the One Development programme and variable
spending as a result of COVID-19 lockdowns. R&D expenditure in
Consumer Healthcare was £113 million.
Royalty income
Royalty
income was £168 million (H1 2020: £142 million), up 18%
AER, 18% CER, primarily driven by higher sales of
Gardasil.
|
|
Other operating income/(expense)
Net
other operating income of £133 million (H1 2020: £1,769
million income) primarily reflected a number of asset disposals
including the disposal of royalty rights on cabozantinib, disposal
of a number of Consumer brands and fair value uplifts on
investments partly offset by accounting charges of £208
million (H1 2020: £841 million) arising from the
re-measurement of the contingent consideration liabilities related
to the acquisitions of the former Shionogi-ViiV Healthcare joint
venture and the former Novartis Vaccines business and the
liabilities for the Pfizer put option and Pfizer and Shionogi
preferential dividends in ViiV Healthcare. This included a
re-measurement charge of £259 million (H1 2020: £778
million) for the contingent consideration liability due to
Shionogi, primarily as a result of the unwinding of the discount
for £185 million and a charge for £74 million from
adjustments to sales forecasts partly offset by updated exchange
rate assumptions. H1 2020 included the net profit on disposal of
the Horlicks and other
Consumer Healthcare brands of £2,815 million, partly offset by
the related loss on sale of the shares in Hindustan Unilever of
£476 million.
|
|
Operating profit
Total
operating profit was £3,368 million in H1 2021 compared with
£4,864 million in H1 2020. This primarily reflected an
unfavourable comparison to the net profit on disposal in Q2 2020 of
the Horlicks and other
Consumer brands and resultant sale of shares in Hindustan Unilever.
This was partly offset by lower major restructuring costs, lower
re-measurement charges on the contingent consideration liabilities
and the unwind in 2020 of the fair market value uplift on inventory
arising on completion of the Consumer Healthcare Joint Venture with
Pfizer.
Excluding
these and other Adjusting items, Adjusted operating profit was
£4,039 million, 9% lower than H1 2020 at AER, but 3% higher at
CER on a turnover decline of 1% CER. The Adjusted operating margin
of 26.0% was 0.4 percentage points lower at AER, but 1.1 percentage
points higher on a CER basis than in H1 2020.
The increase in Adjusted operating profit primarily reflected the
benefit from incremental pandemic adjuvant sales, sales growth in
Pharmaceuticals and tight control of ongoing costs including
reduced promotional and variable spending across all three
businesses as a result of the COVID-19 lockdowns, favourable legal
settlements compared to increased legal costs in 2020 and benefits
from continued restructuring across the business. This was partly
offset by lower non-pandemic sales in Vaccines, primarily
Shingrix, an adverse mix in Vaccines as well as higher
supply chain costs and under-recoveries, divestments in Consumer
Healthcare and increased investment in R&D across Vaccines and
Pharmaceuticals.
Contingent
consideration cash payments which are made to Shionogi and other
companies reduce the balance sheet liability and hence are not
recorded in the income statement. Total contingent consideration
cash payments in H1 2021 amounted to £426 million (H1 2020:
£455 million). This included cash payments made to Shionogi of
£419 million (H1 2020: £445 million).
Adjusted operating profit by business
Pharmaceuticals
operating profit was £2,360 million, up 9% AER, 22% CER on a
turnover increase of 2% CER. The operating margin of 29.1% was 3.7
percentage points higher at AER than in H1 2020 and 5.0 percentage
points higher on a CER basis. This primarily reflected price
benefits in Pharmaceuticals, including the benefit from a prior
period RAR adjustment, as well as reduced supply chain costs, the
tight control of ongoing costs, reduced variable spending as a
result of the COVID-19 lockdowns, a favourable legal settlement in
2021 compared to increased legal costs in 2020 and the continuing
benefit of restructuring. This was partly offset by increased
investment in R&D.
Vaccines
operating profit was £820 million, down 27% AER, 17% CER on
flat turnover at CER. The operating margin of 29.3% was 8.9
percentage points lower at AER than in H1 2020 and 6.7 percentage
points lower on a CER basis. This was primarily driven by higher
supply chain costs resulting from lower demand and adverse mix due
to Shingrix sales in the
US, along with higher R&D spend to support key strategic
priorities. This was partly offset by pandemic adjuvant beneficial
mix and higher royalty income.
Consumer
Healthcare operating profit was £1,033 million, down 20% AER,
13% CER on a turnover decrease of 7% CER. The operating margin of
22.4% was 2.1 percentage points lower at AER and 1.4 percentage
points lower on a CER basis than in H1 2020. This primarily
reflected the impact of divestments (1.7 percentage points),
increased advertising and promotion investment to resume
pre-COVID-19 levels and increased commodity costs and investment
into manufacturing sites, partially offset by synergy benefits from
the Pfizer Joint Venture integration, price increases and tight
cost control.
Net finance costs
Total
net finance costs were £376 million compared with £416
million in H1 2020. Adjusted net finance costs were £375
million compared with £414 million in H1 2020. The decrease is
primarily as a result of reduced interest expense from lower debt
levels and favourable movements in foreign exchange rates, partly
offset by an adverse comparison to a fair value gain on interest
rate swaps in the 2020 comparator and lower interest income on
overseas cash post-closing of the divestment of Horlicks and other Consumer Healthcare
nutrition products in India and a number of other
countries.
Share of after tax profits of associates and joint
ventures
The
share of after tax losses of associates and joint ventures was
£32 million (H1 2020: £28 million profits).
Loss on disposal of interest in associates
The net
loss on disposal of interests in associates was £36 million,
primarily driven by a loss of disposal of our interest in the
associate Innoviva Inc.
Taxation
The
charge of £190 million represented an effective tax rate on
Total results of 6.4% (H1 2020: 8.0%) and reflected the different
tax effects of the various Adjusting items, including a credit of
£325 million in Q2 2021 resulting from the revaluation of
deferred tax assets following enactment of the proposed change of
UK corporation tax rate from 19% to 25% (effective 1 April 2023).
H1 2020 reflected the disposal of the Horlicks and other Consumer brands and
the subsequent disposal of shares received in Hindustan Unilever.
Tax on Adjusted profit amounted to £684 million and
represented an effective Adjusted tax rate of 18.5% (H1 2020:
16.3%).
Issues
related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2020. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods which are open and not yet
agreed by tax authorities. The ultimate liability for such matters
may vary from the amounts provided and is dependent upon the
outcome of agreements with relevant tax authorities.
Non-controlling interests
The
allocation of Total earnings to non-controlling interests amounted
to £330 million (H1 2020: £291 million). The increase was
primarily due to an increased allocation of ViiV Healthcare profits
of £136 million (H1 2020: £64 million), including reduced
credits for re-measurement of contingent consideration liabilities,
partly offset by a reduced allocation of Consumer Healthcare Joint
Venture profits of £163 million (H1 2020: £196
million).
The
allocation of Adjusted earnings to non-controlling interests
amounted to £462 million (H1 2020: £549 million). The
reduction in allocation primarily reflected a reduced allocation of
Consumer Healthcare Joint Venture profits of £222 million (H1
2020: £277 million) and a reduced allocation of ViiV
Healthcare profits of £209 million (H1 2020: £241
million).
Earnings per share
Total
EPS was 49.4p, compared with 77.0p in H1 2020. This primarily
reflected an unfavourable comparison to the net profit on disposal
in Q2 2020 of the Horlicks
and other Consumer brands partly offset by the related loss on sale
of the shares in Hindustan Unilever, as well as by a credit of
£325 million to Taxation in Q2 2021 resulting from the
revaluation of deferred tax assets following enactment of the
proposed change of UK corporation tax rate from 19% to 25%
(effective 1 April 2023), lower major restructuring costs and lower
re-measurement charges on the contingent consideration
liabilities.
Adjusted
EPS was 51.0p compared with 56.9p in H1 2020, down 10% AER but up
2% CER, on a 3% CER increase in Adjusted operating profit
reflecting incremental pandemic adjuvant sales, sales increases in
Pharmaceuticals, tight cost control and favourable legal
settlements, lower interest costs and a lower non-controlling
interest allocation of Consumer Healthcare and ViiV profits, partly
offset by lower non-pandemic sales in Vaccines, primarily
Shingrix and a higher
effective tax rate. The contribution to growth from COVID-19
solutions was approximately 7% AER, 7% CER.
Currency impact on H1 2021 results
The
results for H1 2021 are based on average exchange rates,
principally £1/$1.39, £1/€1.15 and £1/Yen 149.
Comparative exchange rates are given on page 59. The period-end
exchange rates were £1/$1.39, £1/€1.17 and
£1/Yen 153.
In the
six months, turnover decreased 7% AER, 1% CER. Total EPS was 49.4p
compared with 77.0p in H1 2020. Adjusted EPS was 51.0p compared
with 56.9p in H1 2020, down 10% AER but up 2% CER. The adverse
currency impact primarily reflected the strengthening in Sterling,
particularly against the US Dollar as well as the Japanese Yen.
Exchange gains or losses on the settlement of intercompany
transactions had a negligible impact on the negative currency
impact of twelve percentage points on Adjusted EPS.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for H1
2021 and H1 2020 are set out below.
|
|
Six months ended 30 June 2021
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Separation
costs
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
15,510
|
|
|
|
|
|
|
15,510
|
|
Cost of sales
|
(5,034)
|
346
|
1
|
62
|
14
|
27
|
|
(4,584)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
10,476
|
346
|
1
|
62
|
14
|
27
|
|
10,926
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and
administration
|
(5,069)
|
|
|
158
|
|
(11)
|
109
|
(4,813)
|
|
Research and
development
|
(2,340)
|
51
|
19
|
28
|
|
|
|
(2,242)
|
|
Royalty income
|
168
|
|
|
|
|
|
|
168
|
|
Other operating
income/(expense)
|
133
|
|
|
|
232
|
(365)
|
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
3,368
|
397
|
20
|
248
|
246
|
(349)
|
109
|
4,039
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance costs
|
(376)
|
|
|
1
|
|
|
|
(375)
|
|
Loss on
disposal of interest in associates
|
(36)
|
|
|
|
|
36
|
|
-
|
|
Share
of after tax profits
of
associates and joint
ventures
|
32
|
|
|
|
|
|
|
32
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
2,988
|
397
|
20
|
249
|
246
|
(313)
|
109
|
3,696
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(190)
|
(77)
|
(4)
|
(53)
|
(64)
|
(275)
|
(21)
|
(684)
|
|
Tax rate %
|
6.4%
|
|
|
|
|
|
|
18.5%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
2,798
|
320
|
16
|
196
|
182
|
(588)
|
88
|
3,012
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
330
|
|
|
|
132
|
|
|
462
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
2,468
|
320
|
16
|
196
|
50
|
(588)
|
88
|
2,550
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
49.4p
|
6.4p
|
0.3p
|
3.9p
|
1.0p
|
(11.7)p
|
1.7p
|
51.0p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average
number
of shares
(millions)
|
4,999
|
|
|
|
|
|
|
4,999
|
|
|
––––––––––––
|
|
|
|
|
|
|
––––––––––––
|
|
Six months ended 30 June 2020
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Separation
costs
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
16,714
|
|
|
|
|
|
|
16,714
|
|
Cost of sales
|
(5,648)
|
351
|
27
|
305
|
106
|
|
|
(4,859)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
11,066
|
351
|
27
|
305
|
106
|
|
|
11,855
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administration
|
(5,625)
|
|
17
|
288
|
(20)
|
6
|
18
|
(5,316)
|
|
Research and development
|
(2,488)
|
34
|
116
|
82
|
|
(1)
|
|
(2,257)
|
|
Royalty income
|
142
|
|
|
|
|
|
|
142
|
|
Other operating income/(expense)
|
1,769
|
|
|
1
|
832
|
(2,602)
|
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
4,864
|
385
|
160
|
676
|
918
|
(2,597)
|
18
|
4,424
|
|
|
|
|
|
|
|
|
|
|
|
Net finance costs
|
(416)
|
|
|
1
|
|
1
|
|
(414)
|
|
Share of after tax profits of associates and joint
ventures
|
28
|
|
|
|
|
|
|
28
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
4,476
|
385
|
160
|
677
|
918
|
(2,596)
|
18
|
4,038
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(357)
|
(73)
|
(28)
|
(152)
|
(114)
|
69
|
(3)
|
(658)
|
|
Tax rate %
|
8.0%
|
|
|
|
|
|
|
16.3%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
4,119
|
312
|
132
|
525
|
804
|
(2,527)
|
15
|
3,380
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
291
|
|
|
|
258
|
|
|
549
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
3,828
|
312
|
132
|
525
|
546
|
(2,527)
|
15
|
2,831
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
77.0p
|
6.3p
|
2.6p
|
10.5p
|
11.0p
|
(50.8)p
|
0.3p
|
56.9p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares (millions)
|
4,971
|
|
|
|
|
|
|
4,971
|
|
|
––––––––––––
|
|
|
|
|
|
|
––––––––––––
|
|
Major restructuring and integration
Within
the Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete.
|
|
Total
Major restructuring charges incurred in H1 2021 were £248
million (H1 2020: £676 million), analysed as
follows:
|
|
|
H1 2021
|
|
H1
2020
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018
major restructuring
programme
(incl. Tesaro)
|
10
|
|
3
|
|
13
|
|
56
|
|
170
|
|
226
|
|
Consumer
Healthcare Joint
Venture
integration
programme
|
75
|
|
2
|
|
77
|
|
139
|
|
17
|
|
156
|
|
Separation
Preparation
restructuring
programme
|
183
|
|
(1)
|
|
182
|
|
279
|
|
3
|
|
282
|
|
Combined
restructuring and
integration
programme
|
4
|
|
(28)
|
|
(24)
|
|
-
|
|
12
|
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
272
|
|
(24)
|
|
248
|
|
474
|
|
202
|
|
676
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
charges of £183 million under the Separation Preparation
programme primarily arose from restructuring of some administrative
and central manufacturing functions as well as commercial
pharmaceuticals and R&D functions.
Cash
charges of £75 million on the Consumer Healthcare Joint
Venture programme primarily related to severance and integration
costs. The non-cash credit in the Combined restructuring and
integration programme primarily reflected a write back on disposal
of a site.
Total
cash payments made in H1 2021 were £408 million (H1 2020:
£331 million), £214 million (H1 2020: £31 million)
relating to the Separation Preparation restructuring programme, a
further £108 million (H1 2020: £135 million) relating to
the Consumer Healthcare Joint Venture integration programme,
£54 million (H1 2020: £100 million) under the 2018 major
restructuring programme including the settlement of certain charges
accrued in previous quarters and £32 million (H1 2020:
£65 million) for the existing Combined restructuring and
integration programme.
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
Pharmaceuticals
|
91
|
|
216
|
|
Vaccines
|
(40)
|
|
196
|
|
Consumer
Healthcare
|
85
|
|
179
|
|
|
136
|
|
591
|
|
Corporate
& central functions
|
112
|
|
85
|
|
|
|
|
|
|
Total
Major restructuring costs
|
248
|
|
676
|
|
|
|
|
|
|
The
analysis of Major restructuring charges by Income statement line
was as follows:
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
Cost of
sales
|
62
|
|
305
|
|
Selling,
general and administration
|
158
|
|
288
|
|
Research
and development
|
28
|
|
82
|
|
Other
operating income
|
-
|
|
1
|
|
|
|
|
|
|
Total
Major restructuring costs
|
248
|
|
676
|
|
|
|
|
|
|
The
benefit in the six months from restructuring programmes was
£0.3 billion, the Consumer Healthcare Joint Venture
integration was £0.1 billion, the benefit from the Separation
Preparation restructuring programme was £0.1 billion and the
benefit from the 2018 Restructuring programme was £0.1
billion.
The
2018 major restructuring programme, including Tesaro, is now
expected to cost £1.6 billion to the end of 2021, with cash
costs of £0.7 billion and non-cash costs of £0.9 billion,
and is expected to deliver annual savings of around £0.45
billion by the end of 2021 (at 2019 rates). These savings are
intended to be fully re-invested to help fund targeted increases in
R&D and commercial support of new products.
The
completion of the Consumer Healthcare Joint Venture with Pfizer is
expected to realise substantial cost synergies, generating total
annual cost savings of £0.5 billion by 2022 for expected cash
costs of £0.7 billion and non-cash charges expected to be
£0.1 billion, plus additional capital expenditure of £0.2
billion. Up to 25% of the cost savings are intended to be
reinvested in the business to support innovation and other growth
opportunities.
The
Group initiated in Q1 2020 a two-year Separation Preparation
programme to prepare for the separation of GSK into two companies:
New GSK, a biopharma company with an R&D approach focused on
science related to the immune system, the use of genetics and new
technologies, and a new leader in Consumer Healthcare. The
programme aims to
|
|
●
|
Drive a
common approach to R&D with improved capital
allocation
|
|
●
|
Align
and improve the capabilities and efficiency of global support
functions to support New GSK
|
|
●
|
Further
optimise the supply chain and product portfolio, including the
divestment of non-core assets. A strategic review of prescription
dermatology is underway
|
|
●
|
Prepare
Consumer Healthcare to operate as a standalone company
|
|
The
programme now expects to deliver £0.8 billion of annual
savings by 2022 and £1.0 billion by 2023, with total costs
estimated at £2.4 billion, of which £1.6 billion is
expected to be cash costs. The proceeds of delivered and
anticipated divestments are largely expected to cover the cash
costs of the programme.
|
|
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £246 million (H1 2020:
£918 million). This included a net £208 million
accounting charge for the re-measurement of the contingent
consideration liabilities related to the acquisitions of the former
Shionogi-ViiV Healthcare joint venture and the former Novartis
Vaccines business and the liabilities for the Pfizer put option and
Pfizer and Shionogi preferential dividends in ViiV
Healthcare.
|
|
Charge/(credit)
|
H1 2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
venture
(including
Shionogi preferential dividends)
|
259
|
|
778
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(90)
|
|
59
|
|
Contingent
consideration on former Novartis Vaccines business
|
39
|
|
4
|
|
Release
of fair value uplift on acquired Pfizer inventory
|
-
|
|
91
|
|
Other
adjustments
|
38
|
|
(14)
|
|
|
|
|
|
|
Total
transaction-related charges
|
246
|
|
918
|
|
|
|
|
|
|
The £259 million charge relating to the contingent
consideration for the former Shionogi-ViiV Healthcare joint venture
represented an increase in the valuation of the contingent
consideration due to Shionogi, primarily as a result of the unwind
of the discount for £185 million and a charge of £74
million primarily from adjustments to sales forecasts partly offset
by updated exchange rate assumptions. The £90 million credit
relating to the ViiV Healthcare put option and Pfizer preferential
dividends represented a reduction in the valuation of the put
option as a result of lower cash following preference dividend
payments and updated exchange rate assumptions.
The
ViiV Healthcare contingent consideration liability is fair valued
under IFRS. The potential impact of the COVID-19 pandemic remains
uncertain and at 30 June 2021, it has been assumed that there will
be no significant impact on the long-term value of the liability.
This position remains under review and the amount of the liability
will be updated in future quarters as further information on the
impact of the pandemic becomes available. An explanation of the
accounting for the non-controlling interests in ViiV Healthcare is
set out on page 11.
Divestments, significant legal charges and other items
Divestments
and other items also included gains from a number of asset
disposals, including the disposal of royalty rights on cabozantinib
and disposal of a number of Consumer brands, fair value gains on
investments and certain other Adjusting items. The Consumer Brands
disposal programme is complete and has delivered net proceeds of
£1.1 billion. In Q2 2021 the net loss on disposal of interests
in associates was £36 million, primarily driven by a loss on
disposal of the interest in the associate Innoviva Inc. A credit of
£12 million (H1 2020: £6 million charge) was recorded for
significant legal matters arising in the quarter. Significant legal
cash payments were £2 million (H1 2020: £6
million).
Separation costs
From Q2
2020, the Group started to report additional costs to prepare for
Consumer Healthcare separation. Separation costs incurred in H1
2021 were £109 million (H1 2020: £18 million). Separation
costs incurred to date were £177 million. Total separation
costs are estimated to be £600-700 million, excluding
transaction costs.
|
|
Cash generation
|
|
Cash flow
|
|
|
Q2 2021
|
|
H1
2021
|
|
H1
2020
|
|
|
|
|
|
|
|
|
Net
cash inflow from operating activities (£m)
|
1,292
|
|
1,623
|
|
3,725
|
|
Free
cash inflow* (£m)
|
316
|
|
313
|
|
2,480
|
|
Free
cash flow growth (%)
|
(84)%
|
|
(87)%
|
|
>100%
|
|
Free
cash flow conversion* (%)
|
23%
|
|
13%
|
|
65%
|
|
Net
debt** (£m)
|
21,921
|
|
21,921
|
|
23,435
|
|
*
|
Free cash flow and free cash flow
conversion are defined on page 67.
|
|
**
|
Net debt is analysed on page
65.
|
|
Q2 2021
The net
cash inflow from operating activities for the quarter was
£1,292 million (Q2 2020: £2,760 million). The decrease
primarily reflected an adverse comparison to the significant
reduction in trade receivables in Q2 2020 as a result of
collections following strong sales in Q1 2020, adverse timing of
returns and rebates and taxes compared to Q2 2020, partly offset by
increased operating profit net of adverse exchange and a lower
seasonal increase in inventory.
Total
cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the quarter were £203
million (Q2 2020: £232 million), of which £177 million
was recognised in cash flows from operating activities and £26
million was recognised in contingent consideration paid within
investing cash flows. These payments are deductible for tax
purposes.
Free
cash inflow was £316 million for the quarter (Q2 2020:
£1,949 million inflow). The decrease primarily reflected an
adverse comparison to the significant reduction in trade
receivables in Q2 2020 as a result of collections following strong
sales in Q1 2020, adverse timing of returns and rebates and taxes
compared to Q2 2020, increased purchases of intangible assets and
reduced proceeds from intangible assets as the Consumer Brands
Disposal programme is now complete. This was partly offset by
increased operating profit, a lower seasonal increase in inventory
and lower dividends to non-controlling interests.
|
|
H1 2021
The net
cash inflow from operating activities for the six months was
£1,623 million (H1 2020: £3,725 million). The decrease
primarily reflected adverse exchange impacts, reduction in trade
receivables in H1 2020 as a result of collections following strong
sales in Q1 2020, adverse timing of returns and rebates and taxes
compared to Q2 2020 and increased inventory, partly offset by
increased operating profit.
Total
cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the six months were £419
million (H1 2020: £445 million), of which £366 million
was recognised in cash flows from operating activities and £53
million was recognised in contingent consideration paid within
investing cash flows. These payments are deductible for tax
purposes.
Free
cash inflow was £313 million for the six months (H1 2020:
£2,480 million inflow). The decrease primarily reflected
adverse exchange impacts, reduction in trade receivables in H1 2020
as a result of collections following strong sales in Q1 2020,
adverse timing of returns and rebates and taxes compared to Q2 2020
increased inventory, increased purchases of intangible assets and
reduced proceeds from intangible assets as the Consumer Brands
Disposal programme is now complete. This was partly offset by
increased operating profit and lower dividends to non-controlling
interests.
|
|
Net debt
At 30
June 2021, net debt was £21.9 billion, compared with
£20.8 billion at 31 December 2020, comprising gross debt of
£25.5 billion and cash and liquid investments of £3.6
billion. Net debt increased due to the dividends paid to
shareholders of £2.1 billion and additional investments of
£0.1 billion, partly offset by £0.3 billion free cash
flow, £0.4 billion proceeds from investments, including
£0.3 billion proceeds from the Innoviva disposal and £0.4
billion of net favourable exchange impacts from the translation of
non-Sterling denominated debt and exchange on other financing
items.
At 30
June 2021, GSK had short-term borrowings (including overdrafts and
lease liabilities) repayable within 12 months of £5.0 billion
with loans of £2.6 billion repayable in the subsequent
year.
|
|
Returns to shareholders
|
|
Quarterly dividends
The
Board has declared a second interim dividend for 2021 of 19 pence
per share (Q2 2020: 19 pence per share).
GSK
recognises the importance of dividends to shareholders and aims to
distribute regular dividend payments that will be determined
primarily with reference to the free cash flow generated by the
business after funding the investment necessary to support the
Group’s future growth.
The
Board currently intends to maintain the dividend for 2021 at the
current level of 80p per share, subject to any material change in
the external environment or performance expectations.
At the
New GSK Investor Update on 23 June GSK set out that from 2022 a
progressive dividend policy will be implemented, guided by a 40 to
60 percent pay-out ratio through the investment cycle. This is a
key part of the capital allocation framework. For 2022, for the
first half of the year, GSK expects to declare a 27p dividend for
the current group. GSK is on track to separate into two companies
early in the second half of 2022. GSK expects the aggregate
dividend, across the two new businesses to be 28p per share for the
second half. In aggregate this would represent on a full year 2022
basis the equivalent of a Group dividend of 55p per share,
representing a 31% decrease from the 80p/share dividend expected
for 2021. This expected, aggregate 55p per share dividend for full
year 2022 is comprised of 44p representing New GSK's policy, and an
expected 11p from the Consumer Healthcare business. Dividend policy
for the new Consumer Healthcare company will be set by its Board of
Directors. In 2023, the first full year of standalone operations
for New GSK, GSK expects to declare a full year dividend of 45p per
share.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 5 October 2021. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by
the Depositary.
The
ex-dividend date will be 19 August 2021, with a record date of 20
August 2021 and a payment date of 7 October 2021.
|
|
|
Paid/
payable
|
|
Pence
per
share
|
|
£m
|
|
|
|
|
|
|
|
|
2021
|
|
|
|
|
|
|
First
interim
|
8 July
2021
|
|
19
|
|
951
|
|
Second
interim
|
7
October 2021
|
|
19
|
|
951
|
|
|
|
|
|
|
|
|
2020
|
|
|
|
|
|
|
First
interim
|
9 July
2020
|
|
19
|
|
946
|
|
Second
interim
|
8
October 2020
|
|
19
|
|
946
|
|
Third
interim
|
14
January 2021
|
|
19
|
|
946
|
|
Fourth
interim
|
8 April
2021
|
|
23
|
|
1,151
|
|
|
|
|
|
|
|
|
|
|
|
80
|
|
3,989
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|
|
|
|
|
|
|
|
|
Q2 2021
millions
|
|
Q2
2020
millions
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
5,004
|
|
4,977
|
|
Dilutive
effect of share options and share awards
|
|
|
56
|
|
46
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
5,060
|
|
5,023
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|
|
|
|
|
|
|
|
|
H1 2021
millions
|
|
H1
2020
millions
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
4,999
|
|
4,971
|
|
Dilutive
effect of share options and share awards
|
|
|
43
|
|
46
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
5,042
|
|
5,017
|
|
At 30
June 2021, 5,005 million shares (30 June 2020: 4,977 million) were
in free issue (excluding Treasury shares and shares held by the
ESOP Trusts). GSK made no share repurchases during the period. The
company issued 0.3 million shares under employee share schemes in
the quarter for proceeds of £4 million (Q2 2020: £3
million).
|
|
At 30
June 2021, the ESOP Trust held 26.8 million GSK shares against the
future exercise of share options and share awards. The carrying
value of £93 million has been deducted from other reserves.
The market value of these shares was £386
million.
At 30
June 2021, the company held 355.2 million Treasury shares at a cost
of £4,969 million, which has been deducted from retained
earnings.
|
|
Financial information
|
|
Income statements
|
|
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
|
|
|
|
TURNOVER
|
8,092
|
|
7,624
|
|
15,510
|
|
16,714
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(2,554)
|
|
(2,449)
|
|
(5,034)
|
|
(5,648)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,538
|
|
5,175
|
|
10,476
|
|
11,066
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,642)
|
|
(2,709)
|
|
(5,069)
|
|
(5,625)
|
|
Research
and development
|
(1,222)
|
|
(1,301)
|
|
(2,340)
|
|
(2,488)
|
|
Royalty income
|
77
|
|
75
|
|
168
|
|
142
|
|
Other
operating income/(expense)
|
(76)
|
|
1,610
|
|
133
|
|
1,769
|
|
|
|
|
|
|
|
|
|
|
OPERATING PROFIT
|
1,675
|
|
2,850
|
|
3,368
|
|
4,864
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
7
|
|
1
|
|
17
|
|
42
|
|
Finance
expense
|
(192)
|
|
(229)
|
|
(393)
|
|
(458)
|
|
Loss on
disposal of interests in associates
|
(36)
|
|
-
|
|
(36)
|
|
-
|
|
Share
of after tax profits of
associates
and joint ventures
|
16
|
|
19
|
|
32
|
|
28
|
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
1,470
|
|
2,641
|
|
2,988
|
|
4,476
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
68
|
|
(201)
|
|
(190)
|
|
(357)
|
|
Tax rate %
|
(4.6)%
|
|
7.6%
|
|
6.4%
|
|
8.0%
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION
|
1,538
|
|
2,440
|
|
2,798
|
|
4,119
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
143
|
|
177
|
|
330
|
|
291
|
|
Profit
attributable to shareholders
|
1,395
|
|
2,263
|
|
2,468
|
|
3,828
|
|
|
|
|
|
|
|
|
|
|
|
1,538
|
|
2,440
|
|
2,798
|
|
4,119
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
27.9p
|
|
45.5p
|
|
49.4p
|
|
77.0p
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share
|
27.6p
|
|
45.0p
|
|
48.9p
|
|
76.3p
|
|
|
|
|
|
|
|
|
|
|
Statement of comprehensive income
|
|
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
|
|
|
|
|
Profit
for the period
|
1,538
|
|
2,440
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
60
|
|
182
|
|
Reclassification
of exchange movements on liquidation or disposal of
overseas
subsidiaries
and associates
|
(10)
|
|
36
|
|
Fair
value movements on cash flow hedges
|
9
|
|
(5)
|
|
Reclassification
of cash flow hedges to income statement
|
2
|
|
51
|
|
Deferred
tax on fair value movements on cash flow hedges
|
(3)
|
|
(3)
|
|
|
|
|
|
|
|
58
|
|
261
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
(3)
|
|
42
|
|
Fair
value movements on equity investments
|
(78)
|
|
224
|
|
Tax on
fair value movements on equity investments
|
(16)
|
|
(24)
|
|
Re-measurement
gains/(losses) on defined benefit plans
|
258
|
|
(1,445)
|
|
Tax on
re-measurement gains/(losses) on defined benefit plans
|
(40)
|
|
279
|
|
|
|
|
|
|
|
121
|
|
(924)
|
|
|
|
|
|
|
Other
comprehensive income/(expense) for the period
|
179
|
|
(663)
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
1,717
|
|
1,777
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
Shareholders
|
1,577
|
|
1,558
|
|
Non-controlling
interests
|
140
|
|
219
|
|
|
|
|
|
|
|
1,717
|
|
1,777
|
|
|
|
|
|
|
Statement of comprehensive income
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
Profit
for the period
|
2,798
|
|
4,119
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
(207)
|
|
360
|
|
Reclassification
of exchange movements on liquidation or disposal of
overseas
subsidiaries
and associates
|
(10)
|
|
36
|
|
Fair
value movements on cash flow hedges
|
(2)
|
|
(23)
|
|
Reclassification
of cash flow hedges to income statement
|
16
|
|
52
|
|
Deferred
tax on fair value movements on cash flow hedges
|
(3)
|
|
(3)
|
|
|
|
|
|
|
|
(206)
|
|
422
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
(37)
|
|
95
|
|
Fair
value movements on equity investments
|
158
|
|
185
|
|
Tax on
fair value movements on equity investments
|
38
|
|
(14)
|
|
Re-measurement
gains/(losses) on defined benefit plans
|
281
|
|
(445)
|
|
Tax on
re-measurement gains/(losses) on defined benefit plans
|
(52)
|
|
92
|
|
|
|
|
|
|
|
388
|
|
(87)
|
|
|
|
|
|
|
Other
comprehensive income for the period
|
182
|
|
335
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
2,980
|
|
4,454
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
Shareholders
|
2,687
|
|
4,068
|
|
Non-controlling
interests
|
293
|
|
386
|
|
|
|
|
|
|
|
2,980
|
|
4,454
|
|
|
|
|
|
|
Pharmaceuticals turnover – three months ended 30 June
2021
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
717
|
25
|
36
|
463
|
22
|
37
|
150
|
23
|
25
|
104
|
41
|
51
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Anoro Ellipta
|
134
|
(4)
|
4
|
77
|
(13)
|
(5)
|
36
|
12
|
19
|
21
|
11
|
16
|
|
Trelegy Ellipta
|
291
|
50
|
64
|
204
|
46
|
64
|
49
|
36
|
36
|
38
|
>100
|
>100
|
|
Nucala
|
292
|
21
|
32
|
182
|
21
|
35
|
65
|
20
|
22
|
45
|
22
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,235
|
4
|
14
|
716
|
(3)
|
8
|
292
|
8
|
11
|
227
|
30
|
43
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Dolutegravir
products
|
1,189
|
4
|
14
|
691
|
(5)
|
6
|
280
|
8
|
12
|
218
|
40
|
54
|
|
Tivicay
|
407
|
9
|
21
|
196
|
(6)
|
5
|
72
|
(17)
|
(15)
|
139
|
78
|
>100
|
|
Triumeq
|
466
|
(20)
|
(13)
|
292
|
(23)
|
(14)
|
112
|
(16)
|
(14)
|
62
|
(16)
|
(11)
|
|
Juluca
|
132
|
17
|
28
|
101
|
12
|
24
|
27
|
29
|
38
|
4
|
>100
|
>100
|
|
Dovato
|
184
|
>100
|
>100
|
102
|
>100
|
>100
|
69
|
>100
|
>100
|
13
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
10
|
-
|
-
|
10
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Cabenuva
|
4
|
-
|
-
|
3
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
32
|
(30)
|
(31)
|
12
|
(22)
|
(18)
|
11
|
-
|
(18)
|
9
|
(53)
|
(48)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-
inflammation
|
233
|
32
|
46
|
179
|
17
|
30
|
17
|
42
|
42
|
37
|
>100
|
>100
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Benlysta
|
214
|
21
|
34
|
179
|
17
|
30
|
17
|
42
|
42
|
18
|
50
|
83
|
|
Sotrovimab
|
16
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
16
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
119
|
55
|
69
|
68
|
45
|
62
|
49
|
58
|
61
|
2
|
>100
|
>100
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Zejula
|
98
|
27
|
38
|
54
|
15
|
30
|
41
|
37
|
40
|
3
|
>100
|
>100
|
|
Blenrep
|
21
|
-
|
-
|
14
|
-
|
-
|
8
|
-
|
-
|
(1)
|
-
|
-
|
|
Jemperli
|
1
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
2,304
|
14
|
25
|
1,426
|
8
|
21
|
508
|
17
|
19
|
370
|
42
|
58
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
1,925
|
(8)
|
-
|
560
|
16
|
29
|
455
|
(8)
|
(6)
|
910
|
(18)
|
(10)
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Established
Respiratory
|
1,089
|
(2)
|
6
|
478
|
27
|
42
|
250
|
(9)
|
(7)
|
361
|
(22)
|
(15)
|
|
Arnuity Ellipta
|
10
|
25
|
50
|
9
|
50
|
67
|
-
|
-
|
-
|
1
|
(50)
|
-
|
|
Avamys/Veramyst
|
63
|
2
|
10
|
-
|
-
|
-
|
20
|
5
|
5
|
43
|
-
|
12
|
|
Flixotide/Flovent
|
105
|
(10)
|
(1)
|
68
|
26
|
39
|
15
|
(12)
|
(12)
|
22
|
(52)
|
(43)
|
|
Incruse Ellipta
|
53
|
(10)
|
(2)
|
29
|
(12)
|
(3)
|
19
|
-
|
-
|
5
|
(29)
|
-
|
|
Relvar/Breo Ellipta
|
312
|
29
|
40
|
153
|
84
|
>100
|
84
|
8
|
10
|
75
|
(7)
|
2
|
|
Seretide/Advair
|
347
|
(18)
|
(11)
|
132
|
(8)
|
3
|
79
|
(30)
|
(27)
|
136
|
(18)
|
(12)
|
|
Ventolin
|
167
|
16
|
27
|
89
|
53
|
74
|
25
|
4
|
13
|
53
|
(15)
|
(11)
|
|
Other
Respiratory
|
32
|
(48)
|
(46)
|
(2)
|
>(100)
|
>(100)
|
8
|
33
|
17
|
26
|
(53)
|
(53)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
102
|
7
|
16
|
-
|
-
|
-
|
35
|
17
|
20
|
67
|
5
|
16
|
|
Augmentin
|
91
|
(9)
|
(1)
|
-
|
-
|
-
|
29
|
38
|
38
|
62
|
(22)
|
(11)
|
|
Avodart
|
85
|
(37)
|
(32)
|
-
|
-
|
-
|
30
|
(23)
|
(21)
|
55
|
(41)
|
(35)
|
|
Imigran/Imitrex
|
26
|
(4)
|
4
|
7
|
(30)
|
(20)
|
12
|
-
|
-
|
7
|
40
|
60
|
|
Lamictal
|
116
|
(14)
|
(6)
|
55
|
(17)
|
(6)
|
28
|
-
|
-
|
33
|
(20)
|
(10)
|
|
Seroxat/Paxil
|
30
|
(17)
|
(8)
|
-
|
-
|
-
|
8
|
-
|
-
|
22
|
(21)
|
(11)
|
|
Valtrex
|
23
|
(8)
|
-
|
2
|
(33)
|
-
|
9
|
29
|
29
|
12
|
(20)
|
(13)
|
|
Other
|
363
|
(14)
|
(7)
|
18
|
(25)
|
(29)
|
54
|
(28)
|
(23)
|
291
|
(10)
|
(2)
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Pharmaceuticals
|
4,229
|
3
|
12
|
1,986
|
10
|
23
|
963
|
3
|
6
|
1,280
|
(7)
|
3
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––––
|
––––––––
|
––––––––
|
–––––––––
|
––––––––
|
––––––––
|
–––––––––
|
––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals turnover – six months ended 30 June
2021
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,336
|
22
|
31
|
849
|
23
|
35
|
293
|
12
|
12
|
194
|
37
|
45
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Anoro Ellipta
|
251
|
(2)
|
4
|
140
|
(7)
|
1
|
72
|
6
|
6
|
39
|
5
|
11
|
|
Trelegy Ellipta
|
539
|
39
|
49
|
377
|
38
|
51
|
94
|
21
|
21
|
68
|
94
|
>100
|
|
Nucala
|
546
|
21
|
29
|
332
|
25
|
37
|
127
|
9
|
9
|
87
|
24
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
2,266
|
(5)
|
1
|
1,313
|
(9)
|
(1)
|
579
|
(2)
|
(2)
|
374
|
5
|
13
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Dolutegravir
products
|
2,179
|
(5)
|
1
|
1,267
|
(11)
|
(2)
|
560
|
(1)
|
-
|
352
|
10
|
19
|
|
Tivicay
|
708
|
(10)
|
(3)
|
359
|
(15)
|
(7)
|
147
|
(24)
|
(23)
|
202
|
19
|
32
|
|
Triumeq
|
902
|
(21)
|
(16)
|
548
|
(23)
|
(16)
|
233
|
(20)
|
(19)
|
121
|
(15)
|
(11)
|
|
Juluca
|
244
|
5
|
12
|
184
|
-
|
9
|
53
|
18
|
20
|
7
|
75
|
75
|
|
Dovato
|
325
|
>100
|
>100
|
176
|
87
|
>100
|
127
|
>100
|
>100
|
22
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
17
|
-
|
-
|
17
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Cabenuva
|
6
|
-
|
-
|
5
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
|
Other
|
64
|
(30)
|
(28)
|
24
|
(18)
|
(13)
|
18
|
(31)
|
(38)
|
22
|
(39)
|
(34)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-
inflammation
|
413
|
26
|
37
|
324
|
16
|
27
|
33
|
27
|
27
|
56
|
>100
|
>100
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Benlysta
|
392
|
20
|
30
|
324
|
16
|
27
|
33
|
27
|
27
|
35
|
52
|
70
|
|
Sotrovimab
|
16
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
16
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
229
|
45
|
53
|
133
|
40
|
53
|
92
|
44
|
44
|
4
|
>100
|
>100
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Zejula
|
186
|
18
|
24
|
105
|
11
|
21
|
77
|
22
|
22
|
4
|
>100
|
>100
|
|
Blenrep
|
42
|
-
|
-
|
28
|
-
|
-
|
15
|
-
|
-
|
(1)
|
-
|
-
|
|
Jemperli
|
1
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
4,244
|
7
|
14
|
2,619
|
4
|
14
|
997
|
6
|
6
|
628
|
21
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
3,867
|
(15)
|
(9)
|
1,080
|
3
|
12
|
916
|
(19)
|
(19)
|
1,871
|
(20)
|
(14)
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Established
Respiratory
|
2,216
|
(9)
|
(3)
|
920
|
11
|
21
|
508
|
(16)
|
(15)
|
788
|
(21)
|
(15)
|
|
Arnuity Ellipta
|
16
|
(6)
|
6
|
13
|
-
|
8
|
-
|
-
|
-
|
3
|
(25)
|
-
|
|
Avamys/Veramyst
|
166
|
(3)
|
4
|
-
|
-
|
-
|
36
|
(5)
|
(5)
|
130
|
(2)
|
6
|
|
Flixotide/Flovent
|
222
|
(7)
|
-
|
138
|
33
|
44
|
31
|
(31)
|
(31)
|
53
|
(42)
|
(36)
|
|
Incruse Ellipta
|
105
|
(9)
|
(4)
|
56
|
(11)
|
(3)
|
37
|
(5)
|
(5)
|
12
|
(14)
|
(7)
|
|
Relvar/Breo Ellipta
|
580
|
10
|
17
|
265
|
34
|
46
|
166
|
1
|
1
|
149
|
(9)
|
(2)
|
|
Seretide/Advair
|
698
|
(14)
|
(10)
|
249
|
-
|
9
|
174
|
(28)
|
(27)
|
275
|
(16)
|
(11)
|
|
Ventolin
|
356
|
(10)
|
(4)
|
201
|
(2)
|
7
|
50
|
(19)
|
(18)
|
105
|
(19)
|
(15)
|
|
Other
Respiratory
|
73
|
(50)
|
(47)
|
(2)
|
>(100)
|
>100
|
14
|
-
|
-
|
61
|
(54)
|
(53)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
202
|
(2)
|
4
|
-
|
-
|
-
|
69
|
1
|
1
|
133
|
(3)
|
6
|
|
Augmentin
|
182
|
(32)
|
(27)
|
-
|
-
|
-
|
52
|
(33)
|
(33)
|
130
|
(32)
|
(25)
|
|
Avodart
|
168
|
(39)
|
(36)
|
1
|
(67)
|
(67)
|
60
|
(32)
|
(31)
|
107
|
(42)
|
(38)
|
|
Imigran/Imitrex
|
51
|
(16)
|
(13)
|
15
|
(40)
|
(36)
|
24
|
(4)
|
(4)
|
12
|
9
|
18
|
|
Lamictal
|
232
|
(15)
|
(9)
|
110
|
(19)
|
(11)
|
56
|
(7)
|
(7)
|
66
|
(14)
|
(8)
|
|
Seroxat/Paxil
|
63
|
(12)
|
(7)
|
-
|
-
|
-
|
16
|
(11)
|
(11)
|
47
|
(13)
|
(6)
|
|
Valtrex
|
45
|
(15)
|
(9)
|
5
|
(29)
|
(14)
|
17
|
6
|
6
|
23
|
(23)
|
(17)
|
|
Other
|
708
|
(20)
|
(15)
|
29
|
(38)
|
(38)
|
114
|
(35)
|
(34)
|
565
|
(15)
|
(9)
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Pharmaceuticals
|
8,111
|
(5)
|
2
|
3,699
|
4
|
14
|
1,913
|
(8)
|
(7)
|
2,499
|
(13)
|
(6)
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––––
|
––––––––
|
––––––––
|
–––––––––
|
––––––––
|
––––––––
|
–––––––––
|
––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines turnover – three months ended 30 June
2021
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
225
|
35
|
46
|
109
|
>100
|
>100
|
96
|
25
|
27
|
20
|
(55)
|
(43)
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Bexsero
|
165
|
53
|
63
|
60
|
>100
|
>100
|
89
|
25
|
28
|
16
|
60
|
90
|
|
Menveo
|
59
|
55
|
71
|
49
|
>100
|
>100
|
5
|
-
|
-
|
5
|
(64)
|
(57)
|
|
Other
|
1
|
(95)
|
(90)
|
-
|
-
|
-
|
2
|
100
|
100
|
(1)
|
>(100)
|
(100)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
33
|
>100
|
>100
|
-
|
-
|
-
|
-
|
-
|
-
|
33
|
>100
|
>100
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Fluarix, FluLaval
|
33
|
>100
|
>100
|
-
|
-
|
-
|
-
|
-
|
-
|
33
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
295
|
(9)
|
1
|
237
|
(12)
|
-
|
44
|
-
|
2
|
14
|
27
|
18
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Shingrix
|
295
|
(9)
|
1
|
237
|
(12)
|
-
|
44
|
-
|
2
|
14
|
27
|
18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Vaccines
|
758
|
21
|
28
|
239
|
78
|
99
|
157
|
(6)
|
(4)
|
362
|
11
|
16
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Infanrix, Pediarix
|
136
|
14
|
24
|
78
|
90
|
>100
|
27
|
(36)
|
(33)
|
31
|
(14)
|
(8)
|
|
Boostrix
|
146
|
92
|
>100
|
66
|
94
|
>100
|
35
|
30
|
33
|
45
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hepatitis
|
110
|
28
|
38
|
64
|
56
|
76
|
25
|
-
|
4
|
21
|
5
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotarix
|
132
|
3
|
9
|
26
|
53
|
76
|
27
|
(4)
|
-
|
79
|
(5)
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synflorix
|
97
|
(6)
|
(2)
|
-
|
-
|
-
|
9
|
(10)
|
(10)
|
88
|
(5)
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Priorix, Priorix Tetra,
Varilrix
|
54
|
-
|
6
|
-
|
-
|
-
|
24
|
(11)
|
(7)
|
30
|
11
|
19
|
|
Cervarix
|
36
|
6
|
9
|
-
|
-
|
-
|
7
|
40
|
40
|
29
|
-
|
3
|
|
Other
|
47
|
68
|
79
|
5
|
>100
|
>100
|
3
|
-
|
(33)
|
39
|
63
|
87
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Vaccines excluding
pandemic vaccines
|
1,311
|
16
|
24
|
585
|
31
|
46
|
297
|
3
|
6
|
429
|
8
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic vaccines
|
260
|
-
|
-
|
211
|
-
|
-
|
-
|
-
|
-
|
49
|
-
|
-
|
|
Pandemic
adjuvant
|
258
|
-
|
-
|
211
|
-
|
-
|
-
|
-
|
-
|
47
|
-
|
-
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Total Vaccines
|
1,571
|
39
|
49
|
796
|
78
|
97
|
297
|
3
|
6
|
478
|
20
|
26
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Vaccines turnover – six months ended 30 June
2021
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
|
–––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
415
|
6
|
12
|
164
|
30
|
41
|
186
|
8
|
9
|
65
|
(31)
|
(22)
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Bexsero
|
299
|
10
|
15
|
91
|
12
|
22
|
174
|
12
|
13
|
34
|
(6)
|
11
|
|
Menveo
|
98
|
26
|
36
|
73
|
62
|
76
|
9
|
(36)
|
(36)
|
16
|
(16)
|
(5)
|
|
Other
|
18
|
(57)
|
(57)
|
-
|
-
|
-
|
3
|
-
|
-
|
15
|
(62)
|
(62)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
51
|
42
|
53
|
-
|
-
|
-
|
-
|
-
|
-
|
51
|
50
|
62
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Fluarix, FluLaval
|
51
|
42
|
53
|
-
|
-
|
-
|
-
|
-
|
-
|
51
|
50
|
62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
622
|
(36)
|
(31)
|
506
|
(42)
|
(36)
|
75
|
17
|
17
|
41
|
8
|
5
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Shingrix
|
622
|
(36)
|
(31)
|
506
|
(42)
|
(36)
|
75
|
17
|
17
|
41
|
8
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Vaccines
|
1,447
|
(6)
|
(2)
|
420
|
(10)
|
(1)
|
343
|
(14)
|
(14)
|
684
|
1
|
4
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Infanrix, Pediarix
|
272
|
(9)
|
(3)
|
142
|
10
|
20
|
67
|
(30)
|
(30)
|
63
|
(15)
|
(9)
|
|
Boostrix
|
240
|
28
|
34
|
109
|
18
|
30
|
71
|
15
|
15
|
60
|
76
|
76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hepatitis
|
205
|
(31)
|
(27)
|
115
|
(32)
|
(25)
|
49
|
(39)
|
(38)
|
41
|
(18)
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotarix
|
246
|
(12)
|
(8)
|
48
|
(17)
|
(9)
|
57
|
(3)
|
(2)
|
141
|
(13)
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synflorix
|
199
|
(12)
|
(10)
|
-
|
-
|
-
|
21
|
(28)
|
(28)
|
178
|
(10)
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Priorix, Priorix Tetra,
Varilrix
|
117
|
5
|
9
|
-
|
-
|
-
|
56
|
-
|
2
|
61
|
11
|
16
|
|
Cervarix
|
81
|
76
|
78
|
-
|
-
|
-
|
15
|
67
|
67
|
66
|
78
|
81
|
|
Other
|
87
|
(5)
|
(3)
|
6
|
(65)
|
(65)
|
7
|
(22)
|
(44)
|
74
|
12
|
18
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Vaccines excluding
pandemic vaccines
|
2,535
|
(14)
|
(9)
|
1,090
|
(25)
|
(18)
|
604
|
(5)
|
(5)
|
841
|
-
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic vaccines
|
260
|
-
|
-
|
211
|
-
|
-
|
-
|
-
|
-
|
49
|
-
|
-
|
|
Pandemic
adjuvant
|
258
|
-
|
-
|
211
|
-
|
-
|
-
|
-
|
-
|
47
|
-
|
-
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Total Vaccines
|
2,795
|
(5)
|
-
|
1,301
|
(11)
|
(3)
|
604
|
(5)
|
(5)
|
890
|
6
|
10
|
|
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
––––––––
|
|
Balance sheet
|
|
|
30 June 2021
£m
|
|
30 June
2020
£m
|
|
31
December 2020
£m
|
|
ASSETS
|
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
|
|
Property,
plant and equipment
|
9,831
|
|
10,490
|
|
10,176
|
|
Right
of use assets
|
758
|
|
941
|
|
830
|
|
Goodwill
|
10,435
|
|
10,998
|
|
10,597
|
|
Other
intangible assets
|
29,333
|
|
31,263
|
|
29,824
|
|
Investments
in associates and joint ventures
|
76
|
|
390
|
|
364
|
|
Other
investments
|
3,159
|
|
2,174
|
|
3,060
|
|
Deferred
tax assets
|
4,711
|
|
4,455
|
|
4,287
|
|
Derivative
financial instruments
|
6
|
|
5
|
|
5
|
|
Other
non-current assets
|
1,136
|
|
946
|
|
1,041
|
|
|
|
|
|
|
|
|
Total non-current assets
|
59,445
|
|
61,662
|
|
60,184
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
Inventories
|
6,330
|
|
6,396
|
|
5,996
|
|
Current
tax recoverable
|
605
|
|
328
|
|
671
|
|
Trade
and other receivables
|
6,902
|
|
7,168
|
|
6,952
|
|
Derivative
financial instruments
|
104
|
|
421
|
|
152
|
|
Liquid
investments
|
59
|
|
87
|
|
78
|
|
Cash
and cash equivalents
|
3,503
|
|
8,166
|
|
6,292
|
|
Assets
held for sale
|
63
|
|
412
|
|
106
|
|
|
|
|
|
|
|
|
Total current assets
|
17,566
|
|
22,978
|
|
20,247
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
77,011
|
|
84,640
|
|
80,431
|
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
Short-term
borrowings
|
(5,041)
|
|
(5,964)
|
|
(3,725)
|
|
Contingent
consideration liabilities
|
(743)
|
|
(804)
|
|
(765)
|
|
Trade
and other payables
|
(14,267)
|
|
(15,450)
|
|
(15,840)
|
|
Derivative
financial instruments
|
(91)
|
|
(245)
|
|
(221)
|
|
Current
tax payable
|
(411)
|
|
(685)
|
|
(545)
|
|
Short-term
provisions
|
(834)
|
|
(776)
|
|
(1,052)
|
|
|
|
|
|
|
|
|
Total current liabilities
|
(21,387)
|
|
(23,924)
|
|
(22,148)
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
|
|
Long-term
borrowings
|
(20,442)
|
|
(25,726)
|
|
(23,425)
|
|
Corporation
tax payable
|
(176)
|
|
(195)
|
|
(176)
|
|
Deferred
tax liabilities
|
(3,587)
|
|
(3,967)
|
|
(3,600)
|
|
Pensions
and other post-employment benefits
|
(3,357)
|
|
(3,999)
|
|
(3,650)
|
|
Other
provisions
|
(653)
|
|
(814)
|
|
(707)
|
|
Derivative
financial instruments
|
(5)
|
|
(24)
|
|
(10)
|
|
Contingent
consideration liabilities
|
(5,017)
|
|
(5,026)
|
|
(5,104)
|
|
Other
non-current liabilities
|
(809)
|
|
(828)
|
|
(803)
|
|
|
|
|
|
|
|
|
Total non-current liabilities
|
(34,046)
|
|
(40,579)
|
|
(37,475)
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
(55,433)
|
|
(64,503)
|
|
(59,623)
|
|
|
|
|
|
|
|
|
NET ASSETS
|
21,578
|
|
20,137
|
|
20,808
|
|
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
|
|
Share
capital
|
1,347
|
|
1,346
|
|
1,346
|
|
Share
premium account
|
3,299
|
|
3,278
|
|
3,281
|
|
Retained
earnings
|
7,379
|
|
6,622
|
|
6,755
|
|
Other
reserves
|
3,352
|
|
2,347
|
|
3,205
|
|
|
|
|
|
|
|
|
Shareholders’ equity
|
15,377
|
|
13,593
|
|
14,587
|
|
|
|
|
|
|
|
|
Non-controlling
interests
|
6,201
|
|
6,544
|
|
6,221
|
|
|
|
|
|
|
|
|
TOTAL EQUITY
|
21,578
|
|
20,137
|
|
20,808
|
|
|
|
|
|
|
|
|
Statement of changes in equity
|
|
|
Share
capital
£m
|
Share
premium
£m
|
Retained
earnings
£m
|
Other
reserves
£m
|
Share-
holders’
equity
£m
|
Non-
controlling
interests
£m
|
Total
equity
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2021
|
1,346
|
3,281
|
6,755
|
3,205
|
14,587
|
6,221
|
20,808
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
2,468
|
|
2,468
|
330
|
2,798
|
|
Other
comprehensive income/(expense)
for
the period
|
|
|
14
|
205
|
219
|
(37)
|
182
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Total
comprehensive income for the period
|
|
|
2,482
|
205
|
2,687
|
293
|
2,980
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
(320)
|
(320)
|
|
Contributions
from non-controlling interests
|
|
|
|
|
|
7
|
7
|
|
Dividends
to shareholders
|
|
|
(2,097)
|
|
(2,097)
|
|
(2,097)
|
|
Shares
issued
|
1
|
18
|
|
|
19
|
|
19
|
|
Realised
after tax profits on disposal of
equity
investments
|
|
|
145
|
(145)
|
-
|
|
-
|
|
Share
of associates and joint ventures
realised
profits on disposal of equity
investments
|
|
|
9
|
(9)
|
-
|
|
-
|
|
Write-down
on shares held by ESOP Trusts
|
|
|
(96)
|
96
|
-
|
|
-
|
|
Share-based
incentive plans
|
|
|
181
|
|
181
|
|
181
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
At 30 June 2021
|
1,347
|
3,299
|
7,379
|
3,352
|
15,377
|
6,201
|
21,578
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2020
|
1,346
|
3,174
|
4,530
|
2,355
|
11,405
|
6,952
|
18,357
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
3,828
|
|
3,828
|
291
|
4,119
|
|
Other
comprehensive income
for
the period
|
|
|
41
|
199
|
240
|
95
|
335
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Total
comprehensive income for
the
period
|
|
|
3,869
|
199
|
4,068
|
386
|
4,454
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
(652)
|
(652)
|
|
Contributions
from non-controlling interests
|
|
|
|
|
|
3
|
3
|
|
Changes
to non-controlling interests
|
|
|
|
|
|
(145)
|
(145)
|
|
Dividends
to shareholders
|
|
|
(2,085)
|
|
(2,085)
|
|
(2,085)
|
|
Shares
issued
|
-
|
26
|
|
|
26
|
|
26
|
|
Realised
after tax profits on disposal of
equity
investments
|
|
|
36
|
(36)
|
-
|
|
-
|
|
Shares
acquired by ESOP Trusts
|
|
78
|
361
|
(439)
|
-
|
|
-
|
|
Write-down
on shares held by ESOP Trusts
|
|
|
(268)
|
268
|
-
|
|
-
|
|
Share-based
incentive plans
|
|
|
179
|
|
179
|
|
179
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
At 30
June 2020
|
1,346
|
3,278
|
6,622
|
2,347
|
13,593
|
6,544
|
20,137
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Cash flow statement – six months ended 30 June
2021
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
|
|
Profit after tax
|
2,798
|
|
4,119
|
|
|
Tax on
profits
|
190
|
|
357
|
|
|
Share
of after tax profits of associates and joint ventures
|
(32)
|
|
(28)
|
|
|
Loss on
disposal of interests in associates
|
36
|
|
-
|
|
|
Net
finance expense
|
376
|
|
416
|
|
|
Depreciation,
amortisation and other adjusting items
|
1,025
|
|
(971)
|
|
|
Increase
in working capital
|
(1,072)
|
|
(476)
|
|
|
Contingent
consideration paid
|
(371)
|
|
(393)
|
|
|
(Decrease)/increase
in other net liabilities (excluding contingent
consideration
paid)
|
(627)
|
|
1,251
|
|
|
|
|
|
|
|
|
Cash generated from operations
|
2,323
|
|
4,275
|
|
|
Taxation
paid
|
(700)
|
|
(550)
|
|
|
|
|
|
|
|
|
Net cash inflow from operating activities
|
1,623
|
|
3,725
|
|
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
|
Purchase
of property, plant and equipment
|
(440)
|
|
(420)
|
|
|
Proceeds
from sale of property, plant and equipment
|
102
|
|
12
|
|
|
Purchase
of intangible assets
|
(575)
|
|
(326)
|
|
|
Proceeds
from sale of intangible assets
|
384
|
|
636
|
|
|
Purchase
of equity investments
|
(122)
|
|
(208)
|
|
|
Proceeds
from sale of equity investments
|
171
|
|
2,871
|
|
|
Purchase
of businesses, net of cash acquired
|
1
|
|
(6)
|
|
|
Contingent
consideration paid
|
(55)
|
|
(62)
|
|
|
Disposal
of businesses
|
(19)
|
|
237
|
|
|
Investment
in associates and joint ventures
|
(1)
|
|
(1)
|
|
|
Proceeds
from disposal of associates and joint ventures
|
277
|
|
-
|
|
|
Interest
received
|
17
|
|
26
|
|
|
Decrease
in liquid investments
|
18
|
|
-
|
|
|
Dividends
from associates and joint ventures
|
9
|
|
14
|
|
|
|
|
|
|
|
|
Net cash (outflow)/inflow from investing activities
|
(233)
|
|
2,773
|
|
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
|
Issue
of share capital
|
19
|
|
26
|
|
|
Increase
in long-term loans
|
-
|
|
2,354
|
|
|
Repayment
of short-term loans
|
(352)
|
|
(3,018)
|
|
|
Repayment
of lease liabilities
|
(108)
|
|
(111)
|
|
|
Interest
paid
|
(439)
|
|
(476)
|
|
|
Dividends
paid to shareholders
|
(2,097)
|
|
(2,085)
|
|
|
Distributions
to non-controlling interests
|
(320)
|
|
(652)
|
|
|
Contributions
from non-controlling interests
|
7
|
|
3
|
|
|
Other
financing items
|
(131)
|
|
278
|
|
|
|
|
|
|
|
|
Net cash outflow from financing activities
|
(3,421)
|
|
(3,681)
|
|
|
|
|
|
|
|
|
(Decrease)/increase in cash and bank overdrafts in the
period
|
(2,031)
|
|
2,817
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at beginning of the period
|
5,261
|
|
4,831
|
|
|
Exchange
adjustments
|
(34)
|
|
28
|
|
|
(Decrease)/increase
in cash and bank overdrafts
|
(2,031)
|
|
2,817
|
|
|
|
|
|
|
|
|
Cash and bank overdrafts at end of the period
|
3,196
|
|
7,676
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at end of the period comprise:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
3,503
|
|
8,166
|
|
|
Cash
and cash equivalents reported in assets held for sale
|
-
|
|
2
|
|
|
|
|
|
|
|
|
|
3,503
|
|
8,168
|
|
|
Overdrafts
|
(307)
|
|
(492)
|
|
|
|
|
|
|
|
|
3,196
|
|
7,676
|
|
|
|
|
|
|
|
|
Segment information
|
|
|
|
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the
Corporate Executive Team (CET). GSK reports results under four
segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and
Consumer Healthcare, and individual members of the CET are
responsible for each segment.
The
Pharmaceuticals R&D segment is the responsibility of the Chief
Scientific Officer and President, R&D and is reported as a
separate segment. The operating profit of this segment excludes the
ViiV Healthcare operating profit (including R&D expenditure)
that is reported within the Pharmaceuticals segment.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
Corporate
and other unallocated turnover and costs include the results of
certain Consumer Healthcare products which are being held for sale
in a number of markets in order to meet anti-trust approval
requirements, together with the costs of corporate
functions.
|
|
Turnover by segment
|
|
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
4,229
|
|
4,102
|
|
3
|
|
12
|
|
Vaccines
|
1,571
|
|
1,133
|
|
39
|
|
49
|
|
Consumer
Healthcare
|
2,292
|
|
2,389
|
|
(4)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
Total
turnover
|
8,092
|
|
7,624
|
|
6
|
|
15
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|
|
Q2 2021
£m
|
|
Q2
2020
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
2,094
|
|
1,886
|
|
11
|
|
25
|
|
Pharmaceuticals
R&D
|
(853)
|
|
(910)
|
|
(6)
|
|
1
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
including R&D
|
1,241
|
|
976
|
|
27
|
|
46
|
|
Vaccines
|
514
|
|
265
|
|
94
|
|
>100
|
|
Consumer
Healthcare
|
498
|
|
521
|
|
(4)
|
|
5
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,253
|
|
1,762
|
|
28
|
|
46
|
|
Corporate
and other unallocated costs
|
(95)
|
|
(13)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,158
|
|
1,749
|
|
23
|
|
43
|
|
Adjusting
items
|
(483)
|
|
1,101
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
1,675
|
|
2,850
|
|
(41)
|
|
(30)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
7
|
|
1
|
|
|
|
|
|
Finance
costs
|
(192)
|
|
(229)
|
|
|
|
|
|
Loss on
disposal of interests in associates
|
(36)
|
|
-
|
|
|
|
|
|
Share
of after tax profits of associates
and
joint ventures
|
16
|
|
19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
1,470
|
|
2,641
|
|
(44)
|
|
(32)
|
|
|
|
|
|
|
|
|
|
|
Turnover by segment
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
8,111
|
|
8,498
|
|
(5)
|
|
2
|
|
Vaccines
|
2,795
|
|
2,938
|
|
(5)
|
|
-
|
|
Consumer
Healthcare
|
4,604
|
|
5,251
|
|
(12)
|
|
(7)
|
|
|
|
|
|
|
|
|
|
|
|
15,510
|
|
16,687
|
|
(7)
|
|
(1)
|
|
Corporate
and other unallocated turnover
|
-
|
|
27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
turnover
|
15,510
|
|
16,714
|
|
(7)
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
4,004
|
|
3,904
|
|
3
|
|
12
|
|
Pharmaceuticals
R&D
|
(1,644)
|
|
(1,745)
|
|
(6)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
including R&D
|
2,360
|
|
2,159
|
|
9
|
|
22
|
|
Vaccines
|
820
|
|
1,123
|
|
(27)
|
|
(17)
|
|
Consumer
Healthcare
|
1,033
|
|
1,287
|
|
(20)
|
|
(13)
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
4,213
|
|
4,569
|
|
(8)
|
|
3
|
|
Corporate
and other unallocated costs
|
(174)
|
|
(145)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
4,039
|
|
4,424
|
|
(9)
|
|
3
|
|
Adjusting
items
|
(671)
|
|
440
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
3,368
|
|
4,864
|
|
(31)
|
|
(21)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
17
|
|
42
|
|
|
|
|
|
Finance
costs
|
(393)
|
|
(458)
|
|
|
|
|
|
Loss on
disposal of interests in associates
|
(36)
|
|
-
|
|
|
|
|
|
Share
of after tax profits of associates
and
joint ventures
|
32
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
2,988
|
|
4,476
|
|
(33)
|
|
(23)
|
|
|
|
|
|
|
|
|
|
|
Legal matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2020. At 30 June 2021,
the Group’s aggregate provision for legal and other disputes
(not including tax matters described on page 22) was £0.2
billion (31 December 2020: £0.3 billion).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to make a reliable estimate of
the expected financial effect, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
developments since the date of the Annual Report 2020 are as
follows:
On 1
June 2021, the Court overseeing the Zofran Multidistrict Litigation
(MDL) in the District of Massachusetts granted GSK’s motion
for summary judgment on federal preemption grounds. The District
Court granted judgment for GSK in all cases pending in the MDL and
closed the MDL proceeding. On 1 July 2021, Plaintiffs filed a
notice to appeal the preemption decision with respect to all cases
in the MDL to the United States Court of Appeals for the First
Circuit.
|
|
Additional information
|
|
Accounting policies and basis of preparation
|
|
This
unaudited Results Announcement contains condensed financial
information for the three and six months ended 30 June 2021, is prepared in accordance with
the Disclosure Guidance and Transparency Rules (DTR) of the
Financial Conduct Authority and United Kingdom adopted IAS34
‘Interim financial reporting’ and should be read in
conjunction with the Annual Report 2020, which was prepared
in accordance with United Kingdom adopted International Financial
Reporting Standards. This Results Announcement has been prepared
applying consistent accounting policies to those applied by the
Group in the Annual Report 2020.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2020.
|
|
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2020 were published
in the Annual Report 2020, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
COVID-19 pandemic
The
potential impact of the COVID-19 pandemic on GSK’s trading
performance and all our principal risks has been assessed with
mitigation plans put in place. In the first half of 2021, as
anticipated, the pandemic impacted Group performance primarily in
demand for Vaccines as a result of governments’
prioritisation of COVID-19 vaccination programmes and of ongoing
containment measures impacting customers’ ability and
willingness to access vaccination services across all regions. We
remain confident in the underlying demand for our Vaccine products
and are encouraged by the rate at which COVID-19 vaccinations are
being deployed in many countries, particularly the US and UK, which
provides support for healthcare systems returning to normal, though
the pace varies in other key markets. We continue to monitor the
situation closely, as this continues to be a very dynamic and
uncertain situation, with the ultimate severity, duration and
impact unknown at this point including potential impacts on trading
results, clinical trials, supply continuity and our employees. The
situation could change at any time and there can be no assurance
that the COVID-19 pandemic will not have a material adverse impact
on the future results of the Group.
|
|
Exchange rates
|
|
GSK
operates in many countries, and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
Q2 2021
|
|
Q2
2020
|
|
H1 2021
|
|
H1
2020
|
|
2020
|
||
|
|
|
|
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.40
|
|
1.25
|
|
1.39
|
|
1.27
|
|
1.29
|
|
|
|
Euro/£
|
1.16
|
|
1.13
|
|
1.15
|
|
1.15
|
|
1.13
|
|
|
|
Yen/£
|
152
|
|
134
|
|
149
|
|
137
|
|
137
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.39
|
|
1.23
|
|
1.39
|
|
1.23
|
|
1.36
|
|
|
|
Euro/£
|
1.17
|
|
1.10
|
|
1.17
|
|
1.10
|
|
1.11
|
|
|
|
Yen/£
|
153
|
|
132
|
|
153
|
|
132
|
|
141
|
|
During Q2 2021 average Sterling exchange rates were stronger
against the US Dollar, the Yen and the Euro compared with the same
period in 2020. During the six months ended 30 June 2021, average
Sterling exchange rates were stronger against the US Dollar and the
Yen but flat against the Euro compared with the same period in
2020. Period-end Sterling exchange rates were stronger against the
US Dollar, the Euro and the Yen compared with the 2020 period-end
rates.
|
|
Net assets
|
|
The
book value of net assets increased by £770 million from
£20,808 million at 31 December 2020 to £21,578 million at
30 June 2021. This primarily reflected the Total profit for the
period, the re-measurement gains on the defined benefit plans and
the increase in the fair value of equity investments exceeding the
adverse exchange movements and the dividends paid during the
period.
The
carrying value of investments in associates and joint ventures at
30 June 2021 was £76 million (31 December 2020: £364
million), with a market value of £76 million (31 December
2020: £364 million). During Q2 2021, the Group sold all of
its shares in Innoviva Inc back to Innoviva for £277
million.
At 30
June 2021, the net deficit on the Group’s pension plans was
£1,882 million compared with £2,104 million at 31
December 2020. The decrease in the net deficit primarily arose from
an increase in the rates used to discount UK pension liabilities
from 1.4% to 1.9%, and US pension liabilities from 2.3% to 2.7%,
partly offset by an increase in the UK inflation rate from 2.8% to
3.1% and lower UK assets.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £870 million (31 December
2020: £960 million).
Contingent
consideration amounted to £5,760 million at 30 June 2021 (31
December 2020: £5,869 million), of which £5,199 million
(31 December 2020: £5,359 million) represented the estimated
present value of amounts payable to Shionogi relating to ViiV
Healthcare and £504 million (31 December 2020: £477
million) represented the estimated present value of contingent
consideration payable to Novartis related to the Vaccines
acquisition.
Of the
contingent consideration payable (on a post-tax basis) to Shionogi
at 30 June 2021, £717 million (31 December 2020: £745
million) is expected to be paid within one year.
|
|
Movements in contingent consideration are as follows:
|
|
H1
2021
|
ViiV Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,359
|
|
5,869
|
|
Re-measurement
through income statement
|
259
|
|
317
|
|
Cash
payments: operating cash flows
|
(366)
|
|
(371)
|
|
Cash
payments: investing activities
|
(53)
|
|
(55)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,199
|
|
5,760
|
|
|
|
|
|
|
H1
2020
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,103
|
|
5,479
|
|
Re-measurement
through income statement
|
778
|
|
806
|
|
Cash
payments: operating cash flows
|
(388)
|
|
(393)
|
|
Cash
payments: investing activities
|
(57)
|
|
(62)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,436
|
|
5,830
|
|
|
|
|
|
|
Contingent liabilities and commitments
|
|
There
were contingent liabilities at 30 June 2021 in respect of
guarantees and indemnities entered into as part of the ordinary
course of the Group’s business. No material losses are
expected to arise from such contingent liabilities. Provision is
made for the outcome of legal and tax disputes where it is both
probable that the Group will suffer an outflow of funds and it is
possible to make a reliable estimate of that outflow. Descriptions
of the significant legal disputes to which the Group is a party are
set out on page 58.
During
the quarter on 14 June 2021 GSK signed an agreement with iTeos
Therapeutics. On 2 July 2021 GSK signed an agreement with Alector.
These agreements result in total contractual commitments of
approximately £956 million for upfront payments as at 30 June
2021 closing Dollar spot rate. The agreement with Alector is
conditional on review by the appropriate regulatory agencies under
the Hart-Scott-Rodino Act.
|
|
Financial instruments fair value disclosures
|
|
The following tables categorise the Group’s financial assets
and liabilities held at fair value by the valuation methodology
applied in determining their fair value. Where possible, quoted
prices in active markets are used (Level 1). Where such prices are
not available, the asset or liability is classified as Level 2,
provided all significant inputs to the valuation model used are
based on observable market data. If one or more of the significant
inputs to the valuation model is not based on observable market
data, the instrument is classified as Level 3. Other investments
classified as Level 3 in the tables below comprise equity
investments in unlisted entities with which the Group has entered
into research collaborations and also investments in emerging life
science companies.
|
|
At 30 June 2021
|
Level 1
£m
|
|
Level 2
£m
|
|
Level 3
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
Financial assets at fair value
|
|
|
|
|
|
|
|
|
Financial
assets at fair value through other
comprehensive
income (FVTOCI):
|
|
|
|
|
|
|
|
|
Other investments designated at FVTOCI
|
2,796
|
|
-
|
|
183
|
|
2,979
|
|
Trade and other receivables
|
-
|
|
1,653
|
|
-
|
|
1,653
|
|
Financial
assets mandatorily at fair value through
profit
or loss (FVTPL):
|
|
|
|
|
|
|
|
|
Other investments
|
-
|
|
-
|
|
180
|
|
180
|
|
Other non-current assets
|
-
|
|
-
|
|
29
|
|
29
|
|
Trade and other receivables
|
-
|
|
60
|
|
-
|
|
60
|
|
Held for trading derivatives that are not in
a
designated and effective hedging
relationship
|
-
|
|
49
|
|
5
|
|
54
|
|
Cash and cash equivalents
|
915
|
|
-
|
|
-
|
|
915
|
|
Derivatives designated and effective as hedging
instruments
|
-
|
|
56
|
|
-
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
3,711
|
|
1,818
|
|
397
|
|
5,926
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities at fair value
|
|
|
|
|
|
|
|
|
Financial
liabilities mandatorily at fair value through
profit
or loss (FVTPL):
|
|
|
|
|
|
|
|
|
Contingent consideration liabilities
|
-
|
|
-
|
|
(5,760)
|
|
(5,760)
|
|
Held for trading derivatives that are not in
a
designated and effective hedging
relationship
|
-
|
|
(78)
|
|
(5)
|
|
(83)
|
|
Derivatives designated and effective as hedging
instruments.
|
-
|
|
(13)
|
|
-
|
|
(13)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
(91)
|
|
(5,765)
|
|
(5,856)
|
|
|
|
|
|
|
|
|
|
|
At 31 December 2020
|
Level 1
£m
|
|
Level 2
£m
|
|
Level 3
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
Financial assets at fair value
|
|
|
|
|
|
|
|
|
Financial assets at fair value through other
comprehensive income (FVTOCI):
|
|
|
|
|
|
|
|
|
Other investments designated at FVTOCI
|
2,281
|
|
-
|
|
658
|
|
2,939
|
|
Trade and other receivables
|
-
|
|
1,942
|
|
-
|
|
1,942
|
|
Financial assets mandatorily measured at fair value
through profit or loss (FVTPL):
|
|
|
|
|
|
|
|
|
Other investments
|
-
|
|
-
|
|
121
|
|
121
|
|
Other non-current assets
|
-
|
|
-
|
|
30
|
|
30
|
|
Trade and other receivables
|
-
|
|
46
|
|
-
|
|
46
|
|
Held for trading derivatives that are not in
a
designated and effective hedging
relationship
|
-
|
|
63
|
|
5
|
|
68
|
|
Cash and cash equivalents
|
3,292
|
|
-
|
|
-
|
|
3,292
|
|
Derivatives designated and effective as hedging
instruments
|
-
|
|
89
|
|
-
|
|
89
|
|
|
|
|
|
|
|
|
|
|
|
5,573
|
|
2,140
|
|
814
|
|
8,527
|
|
|
|
|
|
|
|
|
|
|
At 31 December 2020
|
Level 1
£m
|
|
Level 2
£m
|
|
Level 3
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities at fair value
|
|
|
|
|
|
|
|
|
Financial
liabilities mandatorily at fair value through
profit
or loss (FVTPL):
|
|
|
|
|
|
|
|
|
Contingent consideration liabilities
|
-
|
|
-
|
|
(5,869)
|
|
(5,869)
|
|
Held for trading derivatives that are not in
a
designated and effective hedging relationship
|
-
|
|
(191)
|
|
(9)
|
|
(200)
|
|
Derivatives designated and effective as hedging
instruments
|
-
|
|
(31)
|
|
-
|
|
(31)
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
(222)
|
|
(5,878)
|
|
(6,100)
|
|
|
|
|
|
|
|
|
|
|
Movements in the six months to 30 June 2021 and the six months to
30 June 2020 for financial instruments measured using Level 3
valuation methods are presented below:
|
|
|
Financial
assets
£m
|
|
Financial
liabilities
£m
|
|
|
|
|
|
|
At 1 January 2021
|
814
|
|
(5,878)
|
|
Gains/(losses) recognised in the income statement
|
47
|
|
(313)
|
|
Gains recognised in other comprehensive income
|
90
|
|
-
|
|
Additions
|
51
|
|
-
|
|
Disposals
|
(10)
|
|
-
|
|
Transfer from Level 3
|
(595)
|
|
-
|
|
Payments in the period
|
-
|
|
426
|
|
|
|
|
|
|
At 30 June 2021
|
397
|
|
(5,765)
|
|
|
|
|
|
|
At 1 January 2020
|
757
|
|
(5,479)
|
|
Gains/(losses) recognised in the income statement
|
6
|
|
(806)
|
|
Gains recognised in other comprehensive income
|
151
|
|
-
|
|
Additions
|
52
|
|
(24)
|
|
Disposals
|
(10)
|
|
-
|
|
Payments in the period
|
-
|
|
455
|
|
|
|
|
|
|
At 30 June 2020
|
956
|
|
(5,854)
|
|
|
|
|
|
|
Net losses of £267 million (H1 2020: net losses of £800
million) reported in other operating income and net gains of
£90 million (H1 2020: net gains of £151 million) reported
in other comprehensive income were attributable to Level 3
financial instruments held at the end of the period. Net gains of
£90 million (H1 2020: £151 million) attributable to Level
3 financial instruments reported in Other comprehensive income as
Fair value movements on equity investments were all attributable to
financial instruments held at the end of the period, of which net
gains of £99 million (H1 2020: nil) arose prior to transfer
from Level 3 on equity investments which transferred to a Level 1
valuation methodology as a result of listing on a recognised stock
exchange during the period. Net gains and losses include the impact
of exchange movements.
Financial liabilities measured using Level 3 valuation methods at
30 June included £5,199 million (H1 2020: £5,436 million)
of contingent consideration for the acquisition in 2012 of the
former Shionogi-ViiV Healthcare joint venture and £504 million
(H1 2020: £349 million) of contingent consideration for the
acquisition of the Novartis Vaccines business in 2015. Contingent
consideration is expected to be paid over a number of years and
will vary in line with the future performance of specified
products, the achievement of certain milestone targets and
movements in certain foreign currencies. The financial liabilities
are measured at the present value of expected future cash flows,
the most significant inputs to the valuation models being future
sales forecasts, the discount rate and the Sterling/US Dollar
exchange.
|
|
The table below shows, on an indicative basis, the income statement
and balance sheet sensitivity to reasonably possible changes in key
inputs to the valuation of the largest contingent consideration
liabilities.
|
|
|
Shionogi-
ViiV Healthcare
|
|
Novartis
Vaccines
|
|
Increase/(decrease) in financial liability
|
£m
|
|
£m
|
|
|
|
|
|
|
10% increase in sales forecasts
|
524
|
|
83
|
|
10% decrease in sales forecasts
|
(520)
|
|
(83)
|
|
1% (100 basis points) increase in discount rate
|
(201)
|
|
(41)
|
|
1% (100 basis points) decrease in discount rate
|
217
|
|
48
|
|
10 cent appreciation of US Dollar
|
296
|
|
2
|
|
10 cent depreciation of US Dollar
|
(253)
|
|
(2)
|
|
10 cent appreciation of Euro
|
112
|
|
21
|
|
10 cent depreciation of Euro
|
(94)
|
|
(18)
|
|
|
|
|
|
|
The Group transfers financial instruments between different levels
in the fair value hierarchy when, as a result of an event or change
in circumstances, the valuation methodology applied in determining
their fair values alters in such a way that it meets the definition
of a different level. There were no transfers between the Level 1
and Level 2 fair value measurement categories. Transfers from Level
3 relate to equity investments in companies which were listed on
stock exchanges during the period.
|
|
The following methods and assumptions were used to measure the fair
value of the significant financial instruments carried at fair
value on the balance sheet:
|
|
|
|
|
|
●
|
Other
investments – equity investments traded in an active market
determined by reference to the relevant stock exchange quoted bid
price; other equity investments determined by reference to the
current market value of similar instruments, recent financing
rounds or the discounted cash flows of the underlying net
assets
|
|
|
|
|
●
|
Trade
receivables carried at fair value – based on invoiced
amount
|
|
|
|
|
●
|
Interest
rate swaps, foreign exchange forward contracts, swaps and options
– based on the present value of contractual cash flows or
option valuation models using market-sourced data (exchange rates
or interest rates) at the balance sheet date
|
|
|
|
|
●
|
Cash
and cash equivalents carried at fair value – based on net
asset value of the funds
|
|
|
|
|
●
|
Contingent consideration for business acquisitions and divestments
– based on present values of expected future cash
flows
|
|
There are no material differences between the carrying value of the
Group's other financial assets and liabilities and their estimated
fair values, with the exception of bonds, for which the carrying
values and fair values are set out in the table below:
|
|
|
30 June 2021
|
|
31 December 2020
|
||||
|
|
|
|
|
|
|
|
|
|
|
Carrying
value
£m
|
|
Fair
value
£m
|
|
Carrying
value
£m
|
|
Fair
value
£m
|
|
|
|
|
|
|
|
|
|
|
Bonds in a designated hedging relationship
|
(6,801)
|
|
(7,202)
|
|
(7,681)
|
|
(8,171)
|
|
Other bonds
|
(17,034)
|
|
(20,718)
|
|
(17,205)
|
|
(21,966)
|
|
|
|
|
|
|
|
|
|
|
|
(23,835)
|
|
(27,920)
|
|
(24,886)
|
|
(30,137)
|
|
|
|
|
|
|
|
|
|
|
The following methods and assumptions are used to estimate the fair
values of financial assets and liabilities which are not measured
at fair value on the balance sheet:
|
|
|
|
|
|
●
|
Company
owned life insurance policies – based on cash surrender
value
|
|
|
|
|
●
|
Receivables
and payables, including put options, carried at amortised cost
– approximates to the carrying amount
|
|
|
|
|
●
|
Liquid
investments – approximates to the carrying
amount
|
|
|
|
|
●
|
Cash
and cash equivalents carried at amortised cost – approximates
to the carrying amount
|
|
|
|
|
●
|
Short-term
loans, overdrafts and commercial paper – approximates to the
carrying amount because of the short maturity of these
instruments
|
|
|
|
|
●
|
Long-term
loans – based on quoted market prices (a Level 1 fair value
measurement) in the case of European and US Medium Term Notes and
other fixed rate borrowings; approximates to the carrying amount in
the case of other fixed rate borrowings and floating rate
bank loans
|
|
Put option
Other
payables in Current liabilities includes the present value of the
expected redemption amount of the Pfizer put option over its
non-controlling interest in ViiV Healthcare of £870 million.
This reflects a number of assumptions around future sales and
profit forecasts, multiples and forecast exchange rates. The
forecast exchange rates used are consistent with market rates at 30
June 2021.
The table below shows on an indicative basis the income statement
and balance sheet sensitivity to reasonably possible changes in the
key inputs to the measurement of this liability.
|
|
Increase/(decrease) in financial liability
|
|
|
ViiV
Healthcare
put
option
£m
|
|
|
|
|
|
|
10%
increase in sales forecasts
|
|
|
91
|
|
10%
decrease in sales forecasts
|
|
|
(91)
|
|
1% (100
basis points) increase in discount rate
|
|
|
(30)
|
|
1% (100
basis points) decrease in discount rate
|
|
|
32
|
|
|
|
|
|
|
Reconciliation of cash flow to movements in net debt
|
|
|
H1 2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
Net
debt at beginning of the period
|
(20,780)
|
|
(25,215)
|
|
|
|
|
|
|
(Decrease)/increase
in cash and bank overdrafts
|
(2,031)
|
|
2,817
|
|
Decrease
in liquid investments
|
(18)
|
|
-
|
|
Net
decrease in short-term loans
|
352
|
|
3,018
|
|
Increase
in long-term loans
|
-
|
|
(2,354)
|
|
Repayment
of lease liabilities
|
108
|
|
111
|
|
Exchange
adjustments
|
525
|
|
(1,769)
|
|
Other
non-cash movements
|
(77)
|
|
(43)
|
|
|
|
|
|
|
(Increase)/decrease
in net debt
|
(1,141)
|
|
1,780
|
|
|
|
|
|
|
Net
debt at end of the period
|
(21,921)
|
|
(23,435)
|
|
|
|
|
|
|
Net debt analysis
|
|
|
30 June 2021
£m
|
|
30 June
2020
£m
|
|
31
December
2020
£m
|
|
|
|
|
|
|
|
|
Liquid
investments
|
59
|
|
87
|
|
78
|
|
Cash
and cash equivalents
|
3,503
|
|
8,166
|
|
6,292
|
|
Cash
and cash equivalents reported in assets held for sale
|
-
|
|
2
|
|
-
|
|
Short-term
borrowings
|
(5,041)
|
|
(5,964)
|
|
(3,725)
|
|
Long-term
borrowings
|
(20,442)
|
|
(25,726)
|
|
(23,425)
|
|
|
|
|
|
|
|
|
Net
debt at end of the period
|
(21,921)
|
|
(23,435)
|
|
(20,780)
|
|
|
|
|
|
|
|
|
Free cash flow reconciliation
|
|
|
Q2 2021
£m
|
|
H1
2021
£m
|
|
H1
2020
£m
|
|
|
|
|
|
|
|
|
Net
cash inflow from operating activities
|
1,292
|
|
1,623
|
|
3,725
|
|
Purchase
of property, plant and equipment
|
(239)
|
|
(440)
|
|
(420)
|
|
Proceeds
from sale of property, plant and equipment
|
65
|
|
102
|
|
12
|
|
Purchase
of intangible assets
|
(422)
|
|
(575)
|
|
(326)
|
|
Proceeds
from disposals of intangible assets
|
56
|
|
384
|
|
636
|
|
Net
finance costs
|
(335)
|
|
(422)
|
|
(450)
|
|
Dividends
from joint ventures and associates
|
9
|
|
9
|
|
14
|
|
Contingent
consideration paid (reported in investing
activities)
|
(26)
|
|
(55)
|
|
(62)
|
|
Distributions
to non-controlling interests
|
(84)
|
|
(320)
|
|
(652)
|
|
Contributions
from non-controlling interests
|
-
|
|
7
|
|
3
|
|
|
|
|
|
|
|
|
Free
cash inflow
|
316
|
|
313
|
|
2,480
|
|
|
|
|
|
|
|
|
Principal risks and uncertainties
The
principal risks and uncertainties affecting the Group are those
described under the headings below. These are detailed in the
‘Principal risks and uncertainties’ section of the
Annual Report 2020. See ‘Additional information’ on
page 59 for risks and uncertainties relating to the COVID-19
pandemic.
|
|
Patient
safety
|
Failure
to appropriately collect, review, follow up, or report human safety
information, including adverse events from all potential sources,
and to act on any relevant findings in a timely
manner.
|
|
|
|
|
Product
quality
|
Failure
by GSK, its contractors or suppliers to ensure appropriate controls
and governance of quality in product development; compliance with
good manufacturing practice or good distribution practice
regulations in commercial or clinical trials manufacture and
distribution activities; compliance with the terms of GSK product
licences and supporting regulatory activities.
|
|
|
|
|
Financial
controls and reporting
|
Failure
to comply with current tax laws or incurring significant losses due
to treasury activities; failure to report accurate financial
information in compliance with accounting standards and applicable
legislation.
|
|
|
|
|
Anti-bribery
and corruption
|
The
risk comprises five sub-risk areas: bribery of public officials by
GSK; bribery of commercial and other non-public entities by GSK;
bribery by third parties acting on behalf of GSK; GSK employees
receiving and/or requesting bribes and/or other undue personal
benefit; other corruption-non-compliance with laws and regulations
related to money laundering or facilitation of tax evasion by third
parties/clients/partners.
|
|
|
|
|
Commercial
practices
|
Failure
to engage in commercial activities that are consistent with the
letter and spirit of the law, industry regulations or the
Group’s requirements relating to sales and promotion of our
medicines and vaccines; appropriate interactions with healthcare
professionals/organisations and patients; legitimate and
transparent transfers of value; and pricing and competition (or
antitrust) regulations in commercial practices, including trade
channel activities and tendering business.
|
|
|
|
|
Non-promotional
engagement
|
Failure
to engage in non-promotional activities that are consistent with
external regulations, internal policies and GSK values regarding
scientific engagement with healthcare professionals and patients,
including communications relating to our medicines or associated
disease areas, appropriate conduct of interactions and legitimacy
and transparency of those interactions.
|
|
|
|
|
Privacy
|
Failure
to collect, secure, use and destroy personal information in
accordance with data privacy laws can lead to harm to individuals
(e.g. financial, stress, prejudice) and GSK (e.g. fines,
operational, financial and reputational).
|
|
|
|
|
Research
practices
|
Failure
to adequately conduct ethical and sound pre-clinical and clinical
research. In addition, failure to engage in scientific activities
that are consistent with the letter and spirit of the law,
industry, or the Group’s requirements. It comprises the
following sub-risks: non-clinical and laboratory research; human
subject research; data integrity; care, welfare and treatment of
animals; human biological samples management; data disclosure;
regulatory filings and engagement; and patents.
|
|
|
|
|
Environment,
health & safety
|
Failure
in management of: execution of hazardous activities; GSK’s
physical assets and infrastructure; handling and processing of
hazardous chemicals and biological agents; control of releases of
substances harmful to the environment in both the short and long
term, leading to incidents which could disrupt our R&D and
supply activities, harm employees, harm the communities and harm
the local environments in which we operate.
|
|
|
|
|
Environmental
sustainability
|
Failure
in management of: physical climate and environmental risks, current
and future regulatory requirements for environmental policies and
taxes, delivery and performance of management environmental
objectives, leading to reduced supply chain resilience, product
life cycle management issues, loss of trust/reputation with
employees, investors, customers, regulators and other stakeholders,
increased costs, loss of sales or market access and negative
impacts on the environment.
|
|
|
|
|
Information
security
|
The
risk that unauthorised disclosure, theft, unavailability or
corruption of GSK’s information or key information systems
may lead to harm to our patients, workforce and customers,
disruption to our business and/or loss of commercial or strategic
advantage, damage to our reputation or regulatory
sanction.
|
|
|
|
|
Supply
continuity
|
Failure
to deliver a continuous supply of compliant finished product;
inability to respond effectively to a crisis incident in a timely
manner to recover and sustain critical operations.
|
|
|
|
|
Transformation
|
Failure
to deliver the plan for successful transformation and separation of
GSK into two competitive standalone companies; New GSK, a biopharma
company and new Consumer Healthcare.
|
|
|
|
|
Reporting definitions
|
|
Total and Adjusted results
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined on page 10 and other non-IFRS measures
are defined below.
Free cash flow
Free
cash flow is defined as the net cash inflow/outflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and dividends paid to non-controlling interests
plus proceeds from the sale of property, plant and equipment and
intangible assets, and dividends received from joint ventures and
associates. It is used by management for planning and reporting
purposes and in discussions with and presentations to investment
analysts and rating agencies. Free cash flow growth is calculated
on a reported basis. A reconciliation of net cash inflow from
operations to free cash flow is set out on page 65.
Free cash flow conversion
Free
cash flow conversion is free cash flow as a percentage of
earnings.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. £%
or AER% represents growth at actual exchange rates.
Pro-forma growth
The
acquisition of the Pfizer consumer healthcare business completed on
31 July 2019 and so GSK’s reported results for H1 2020
included six months of results of the former Pfizer consumer
healthcare business from 1 January 2020.
The
Group has presented in this Results Announcement pro-forma growth
rates at CER in H1 2020 for sales excluding brands divested/under
review for Consumer Healthcare and sales for certain categories of
consumer healthcare products taking account of this transaction.
Pro-forma growth rates for the half year are calculated comparing
reported results for H1 2020, calculated applying the exchange
rates used in the comparative period, with the results for H1 2019
adjusted to include the equivalent six months of results of the
former Pfizer consumer healthcare business during H1 2019, as
consolidated (in US$) and included in Pfizer’s US GAAP
results.
2 year Compound Annual Growth Rate
CAGR is defined as the compound annual growth rate and shows the
annualised average rate of pro-forma revenue growth between two
given years, assuming growth takes place at an exponentially
compounded rate. For Consumer Healthcare, the 2 year revenue CAGR
has been shared showing the annualised average rate of pro-forma
revenue growth between 2019 and 2021.
COVID-19 solutions
COVID-19 solutions include the sales of pandemic adjuvant and other
COVID-19 solutions including vaccine manufacturing and sotrovimab
and the associated costs but does not include reinvestment in
R&D. This categorisation is used by management and we believe
is helpful to investors through providing clarity on the results of
the Group by showing the contribution to growth from COVID-19
solutions.
|
|
Brand names and partner acknowledgements
Brand
names appearing in italics throughout this document are trademarks
of GSK or associated companies or used under licence by the
Group.
|
|
Outlook, assumptions and cautionary statements
|
|
2021 guidance
Our
guidance range for 2021 is a decline of mid to high-single digit
percent adjusted EPS at CER and excludes any contribution from
COVID-19 related solutions.
2021-2026 sales and adjusted operating profit growth outlooks, 2026
cash generated from operations outlook, 2031 sales ambition and
2021-2023 dividend expectations
In June
2021, GSK announced that it expected New GSK to deliver sales growth and adjusted operating
profit growth of more than 5% and more than 10%, respectively, CAGR
at constant exchange rates over the five year period 2021-2026
(with 2021 as the base year). These financial outlooks exclude any
contribution from COVID-19 related revenues. New GSK expects to
improve adjusted operating margin from the mid-20s% in 2021 to over
30% by 2026 and cash generated from operations is expected
to exceed £10 billion by 2026. By
2031, New GSK aims to deliver sales of more than £33 billion
(at constant exchange rates).
Assumptions related to 2021 guidance, 2021-2026 outlooks, 2031
sales ambition and 2021-2023 dividend expectations
In
outlining the guidance for 2021 and future five-year 2021-26
outlook, 2031 ambition and dividend expectations, the Group has
made certain assumptions about the healthcare sector (including
regarding possible governmental, legislative and regulatory
reform), the different markets and competitive landscape in which
it operates and the delivery of revenues and financial benefits
from its current portfolio, its development pipeline of drugs and
vaccines, its restructuring programmes and its plans for the
separation of Consumer Healthcare.
2021 guidance
The
Group has made planning assumptions for 2021 that healthcare
systems and consumer trends will approach normality in the second
half of the year, and we expect turnover to be flat to low single
digit growth for the Pharmaceuticals and Vaccines businesses and
low to mid-single digit growth for Consumer Healthcare excluding
brands divested/under review. These planning assumptions as well as
earnings guidance and dividend expectations assume no material
interruptions to supply of the Group’s products, no material
mergers, acquisitions or disposals, no material litigation or
investigation costs for the Company (save for those that are
already recognised or for which provisions have been made), no
share repurchases by the Company, and no change in the
Group’s shareholdings in ViiV Healthcare. The assumptions
also assume no material changes in the healthcare environment. The
2021 guidance factors in all divestments and product exits
announced to date, including product divestments planned in
connection with the formation of the Consumer Healthcare Joint
Venture with Pfizer, and the non-core divestments planned to fund
the cash costs of the Separation Preparation restructuring
programme.
The
Group’s guidance assumes successful delivery of the
Group’s integration and restructuring plans. It also assumes
that the integration and investment programmes following the
creation of the Consumer Healthcare Joint Venture with Pfizer are
delivered successfully. Material costs for investment in new
product launches and R&D have been factored into the
expectations given. Given the potential development options in the
Group’s pipeline, the outlook may be affected by additional
data-driven R&D investment decisions. The guidance is given on
a constant currency basis.
New GSK’s revenue, operating profit, operating margin and
cash flow outlooks, revenue ambition and dividend
expectations
GSK
expects and assumes the next several years to be challenging for
the healthcare industry with continued uncertainty related to the
impact of the COVID-19 pandemic on adult vaccinations and continued
pressure on pricing of pharmaceuticals. GSK also expects volume
demand for its products to increase, particularly for Shingrix in the US, as healthcare
systems are expected to return to normal following disruption from
governments’ prioritisation of COVID-19 vaccination
programmes and ongoing measures to contain the pandemic, and for
Shingrix in
China.
The
assumptions for New GSK’s revenue, operating profit,
operating margin and cash flow outlooks, revenue ambition and
dividend expectations assume successful delivery of the ongoing and
planned integration and restructuring plans and the planned
demerger of Consumer Healthcare; the delivery of revenues and
financial benefits from its current and development pipeline
portfolio of drugs and vaccines (which have been assessed for this
purpose on a risk-adjusted basis, as described further below);
regulatory approvals of the pipeline portfolio of drugs and
vaccines that underlie these expectations (which have also been
assessed for this purpose on a risk-adjusted basis, as described
further below); no material interruptions to supply of the
Group’s products; no material mergers, acquisitions or
disposals or other material business development transactions; no
material litigation or investigation costs for the company (save
for those that are already recognised or for which provisions have
been made); no share repurchases by the company; and no change in
the shareholdings in ViiV Healthcare. GSK assumes no premature loss
of exclusivity for key products over the period.
The
assumptions for New GSK’s revenue, operating profit,
operating margin and cash flow outlooks, revenue ambition and
dividend expectations also factor in all divestments and product
exits announced to date as well as material costs for investment in
new product launches and R&D. Pipeline risk-adjusted sales are
based on the latest internal estimate of the probability of
technical and regulatory success for each asset in
development.
Notwithstanding
these outlooks and expectations, there is still uncertainty as to
whether our assumptions, targets, outlooks expectations and
ambitions will be achieved, including based on the other
assumptions outlined above.
All
outlook and ambition statements are given on a constant currency
basis and use 2021 forecast exchange rates as a base, assuming a
continuation of Q1 2021 closing rates (£1/$1.38,
£1/€1.17, £1/Yen 152). 2021-2026 outlook refers to
the 5 years to 2026 with 2021 as the base year.
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, ambitions
and expectations described in this report are achievable based on
those assumptions. However, given the forward-looking nature of
these guidance, outlooks, ambitions and expectations, they are
subject to greater uncertainty, including potential material
impacts if the above assumptions are not realised, and other
material impacts related to foreign exchange fluctuations,
macro-economic activity, the impact of outbreaks, epidemics or
pandemics, such as the COVID-19 pandemic and ongoing challenges and
uncertainties posed by the COVID-19 pandemic for businesses and
governments around the world, changes in legislation, regulation,
government actions or intellectual property protection, product
development and approvals, actions by our competitors, and other
risks inherent to the industries in which we operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’, ‘aim’,
‘ambition’ and other words and terms of similar meaning
in connection with any discussion of future operating or financial
performance. In particular, these include statements relating to
future actions, prospective products or product approvals, future
performance or results of current and anticipated products, sales
efforts, expenses, the outcome of contingencies such as legal
proceedings, dividend payments and financial results. Other than in
accordance with its legal or regulatory obligations (including
under the Market Abuse Regulation, the UK Listing Rules and the
Disclosure and Transparency Rules of the Financial Conduct
Authority), the Group undertakes no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise. The reader should, however, consult any
additional disclosures that the Group may make in any documents
which it publishes and/or files with the SEC. All readers, wherever
located, should take note of these disclosures. Accordingly, no
assurance can be given that any particular expectation will be met
and investors are cautioned not to place undue reliance on the
forward-looking statements.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2020 and any impacts of the COVID-19 pandemic. Any
forward looking statements made by or on behalf of the Group speak
only as of the date they are made and are based upon the knowledge
and information available to the Directors on the date of this
report.
|
|
Directors’ responsibility statement
The Board of Directors approved this Half-yearly Financial Report
on 28 July 2021.
The Directors confirm that to the best of their knowledge the
unaudited condensed financial information has been prepared in
accordance with IAS 34 as contained in UK-adopted International
Financial Reporting Standards (IFRS) and that the interim
management report includes a fair review of the information
required by DTR 4.2.7 and DTR 4.2.8.
After making enquiries, the Directors considered it appropriate to
adopt the going concern basis in preparing this Half-yearly
Financial Report.
The Directors of GlaxoSmithKline plc are as follows:
|
|
|
|
|
|
Sir Jonathan Symonds
|
Non-Executive Chairman, Nominations & Corporate Governance
Committee Chair
|
|
Dame Emma Walmsley
|
Chief Executive Officer (Executive Director)
|
|
Iain Mackay
|
Chief Financial Officer (Executive Director)
|
|
Dr Hal Barron
|
Chief Scientific Officer and President, R&D (Executive
Director)
|
|
Vindi Banga
|
Senior Independent Non-Executive Director
|
|
Charles Bancroft
|
Independent Non-Executive Director, Audit & Risk
Committee Chair
|
|
Dr Anne Beal
|
Independent Non-Executive Director
|
|
Dr Vivienne Cox
|
Independent Non-Executive Director, Workforce Engagement
Director
|
|
Lynn Elsenhans
|
Independent Non-Executive Director, Corporate Responsibility
Committee Chair
|
|
Dr Laurie Glimcher
|
Independent Non-Executive Director
|
|
Dr Jesse Goodman
|
Independent Non-Executive Director, Science Committee
Chair
|
|
Urs Rohner
|
Independent Non-Executive Director, Remuneration Committee
Chair
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By order of the Board
|
|
|
Emma Walmsley
Chief Executive Officer
28 July 2021
|
Iain Mackay
Chief Financial Officer
|
|
Independent review report to GlaxoSmithKline plc
|
|
We have
been engaged by GlaxoSmithKline plc (“the Company”) to
review the condensed financial information in the Results
Announcement of the Company for the three and six months ended 30
June 2021.
|
|
What we have reviewed
|
|
|
The
condensed financial information comprises:
|
|
|
●
|
the
income statements and statements of comprehensive income for the
three and six month periods ended 30 June 2021 on pages 46 to
48;
|
|
●
|
the
balance sheet as at 30 June 2021 on page 53;
|
|
●
|
the
statement of changes in equity for the six month period then ended
on page 54;
|
|
●
|
the
cash flow statement for the six month period then ended on page 55;
and
|
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial statements on pages 49 to 52 and
56 to 64.
|
|
|
|
|
We have
read the other information contained in the Results Announcement,
including the non-IFRS measures contained on pages 49 to 52 and 56
to 64, and considered whether it contains any apparent
misstatements or material inconsistencies with the information in
the condensed set of financial statements.
This
report is made solely to the Company in accordance with
International Standard on Review Engagements (UK and Ireland) 2410
“Review of Interim Financial Information Performed by the
Independent Auditor of the Entity” issued by the Financial
Reporting Council. Our work has been undertaken so that we might
state to the Company those matters we are required to state to it
in an independent review report and for no other purpose. To the
fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Company, for our review
work, for this report, or for the conclusions we have
formed.
Directors’ responsibilities
The
Results Announcement of the Company, including the condensed
financial statements, is the responsibility of, and has been
approved by, the directors. The directors are responsible for
preparing the Results Announcement of the Company in accordance
with the Disclosure Guidance and Transparency Rules of the United
Kingdom’s Financial Conduct Authority.
As
disclosed in note 1, the annual financial statements of the Company
are prepared in accordance with United Kingdom adopted
International Financial Reporting Standards. The condensed
financial statements included in this Results Announcement have
been prepared in accordance with United Kingdom adopted
International Accounting Standard 34, “Interim Financial
Reporting”.
Our responsibility
Our
responsibility is to express to the Company a conclusion on the
condensed financial statements in the Results Announcement based on
our review.
Scope of review
We
conducted our review in accordance with International Standard on
Review Engagements (UK and Ireland) 2410 “Review of Interim
Financial Information Performed by the Independent Auditor of the
Entity” issued by the Financial Reporting Council for use in
the United Kingdom. A review of interim financial information
consists of making inquiries, primarily of persons responsible for
financial and accounting matters, and applying analytical and other
review procedures. A review is substantially less in scope than an
audit conducted in accordance with International Standards on
Auditing (UK) and consequently does not enable us to obtain
assurance that we would become aware of all significant matters
that might be identified in an audit. Accordingly, we do not
express an audit opinion.
Conclusion
Based
on our review, nothing has come to our attention that causes us to
believe that the condensed financial statements in the Results
Announcement for the three and six months ended 30 June 2021 are
not prepared, in all material respects, in accordance with United
Kingdom adopted International Accounting Standard 34 and the
Disclosure Guidance and Transparency Rules of the United
Kingdom’s Financial Conduct Authority.
Deloitte LLP
Statutory
Auditor
London,
United Kingdom
28 July
2021
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
28, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|